Oncology and Carcinogenesis articles for United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 2006

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
24 12.54
Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer 0.08
Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation to Potentiate Antitumor Immunity 0.05
Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy 0.40
Nanodiamond-Mediated Targeted Delivery of Nanobodies and Immunostimulatory RNA for Breast Cancer Therapy 0.38
Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells 0.06
Synergistic Gene Immunotherapy for Lung Cancer via Targeted Nanomedicine Restoring Genetic Tumor Suppression and Activating STING Pathway 0.13
A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection 1.00
An Organoid Biosensing Platform for Personalized Prognosis of Bladder Cancer 1.00
Chemotherapeutic Spherical Nucleic Acids 1.00
A Myeloid Cell-Targeted Immunostimulant Cocktail (MyTai) Enhances Cancer Immunotherapy 0.65
Mito-Specific “Trojan Horse” Nanotherapy: Synergistic Antitumor Immunotherapy via Dual Modulation Mitochondrial Metabolism and Glycolysis 0.29
Exploring the Potentials of Silver Nanoparticles in Overcoming Cisplatin Resistance in Lung Adenocarcinoma: Insights from Proteomic and Xenograft Mice Studies 0.17
SnOx Nanoflakes as Enhanced Near-Infrared Photothermal Therapy Agents Synthesized from Electrochemically Oxidized SnS2 Powders 0.38
A Spatiotemporally Controllable DNA Hydrogel Mesh for Focused Antimetastasis Therapy of Cancer 0.05
Endogenous Targeting of Lipid Nanoparticles to Kidney Tumors 1.00
Tailoring Long-Lived Charge Separation Enables Efficient Light-to-Heat Conversion for Efficient Cancer Therapy 0.04
Multiplexed Nanoscale Viscoelastic Mapping at Multiple Time Scales of Melanoma Cells as a Label-Free Cancer Biomarker 1.00
Customized Nanofibers with Lung-Targeting and -ReCustomized Nanofibers with Lung-Targeting and -Retention Properties for Treating Isolated Triple-Negative Breast Cancer Pulmonary Metastasestention Properties for Treating Isolated Triple-Negative Breast Cancer Pulmonary Metastases 1.00
Hybrid Cell Membrane-Functionalized Nanoagents Synergistically Enhance Cuproptosis-Mediated Immunotherapy by Dual Modulation of Glycolytic Metabolism and Tumor Microenvironments 0.08
Overcoming Radiotherapy Resistance in Chordoma through the Synergistic Action of Selenium-Containing Nanoparticles and THZ1 0.03
Advanced Cancer Liquid Biopsy Platform for miRNA Detection in Extracellular Vesicles Using CRISPR/Cas13a and Gold Nanoarrays 0.92
Thermosensitive Hydrogel Sustaining the Release of Lymph-Draining Oligonucleotide Adjuvant Polyplex Micelles Improves Systemic Cancer Immunotherapy 0.86
Biodegradable PLGA Particles with Confined Water for Safe Photothermal Biomodulation 1.00
3D Tumor-Mimicking Phantom Models for Assessing NIR I/II Nanoparticles in Fluorescence-Guided Surgical Interventions 1.00
16 12.29
A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer 1.00
Bovine serum albumin-stabilized nano-delivery system potentiates targeted anti-angiogenic therapy and synergistic photo-immunotherapy to restrict lung cancer metastasis 0.18
Structure-functionality relationship of collagen-fibrin interpenetrating hydrogels for engineered tumor-stroma models 1.00
Restoring Antitumor Immunity by Reprogramming Abnormal Lipid Metabolism in the Tumor Microenvironment Using Irisin-Manganese Co-loaded Nanoparticles 0.08
Dual Inhibition of KRAS G12D and PI3K/BRD4 Signaling Overcomes Therapeutic Resistance in Pancreatic Cancer 1.00
MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism 0.73
Discovery of small molecules and a druggable groove that regulate DNA binding and release of the AP-1 transcription factor ΔFOSB 1.00
Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity 0.23
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity 1.00
Collagen nanofiber alignment attenuates leader-follower energetic and metabolic differences during collective migration in pancreatic cancer 1.00
Changes in patient-reported quality of life after lobectomy versus sublobar resection 0.97
Fibronectin composition and transglutaminase 2 cross-linking cooperatively regulate ovarian cancer cell adhesion in ECM-mimetic constructs 1.00
Macroporous Hydrogel-Based mRNA Cancer Vaccine for In Situ Recruitment and Modulation of Dendritic Cells 1.00
A hypoxia-leveraged near-IR theranostic nanomedicine enables imaging-guided tumor diagnosis and photothermal therapy 1.00
Collagen fiber density observed in metastatic ovarian cancer promotes tumor cell adhesion 1.00
Endogenous nanoplatforms for tumor photoimmunotherapy: Hypoxia modulation and STING pathway activation 0.10
7 4.03
Resonance Energy Transfer–Driven Photothermal Nanoagent Enables Melanoma Ablation Under Low-Power Near-Infrared Irradiation 0.96
Electronic Structure Modulation of Zn–Y Dual Single-Atom Sites for Synergistic Sonodynamic/Catalytic Cancer Therapy: “One Heart (Zn) and One Mind (Y)” 0.09
Structurally Engineered Ferrous Metal–Organic Framework as a Chemodynamic Therapy Nanoagent for Concurrent Hydroxyl Radical and Singlet Oxygen Generation 1.00
MPI‐Guided Photothermal Therapy of Prostate Cancer Using Stem Cell Delivery of Magnetotheranostic Nanoflowers 0.63
Cold Quad-Modal Nanocomplex for Precise and Quantitative In Vivo Stem Cell Tracking 1.00
A Single-Metal-Doped Nanoplatform for Ferroptosis-Driven cGAS-STING Pathway Activation in Hepatocellular Carcinoma Immunotherapy 0.07
Therapeutic Adoptive Cell Transfer (ACT) Vaccine Patch: Bioengineered Tumor Cells Prime Macrophage Immunoregulation to Prevent Postsurgical Tumor Recurrence and Metastasis 0.29
11 4.66
Bone-Targeted Nanoparticles Enable Metabolic Reprogramming via cGAS Lactylation Suppression to Restore Chemosensitivity and Antitumor Immunity in Osteosarcoma 0.06
A Tumor-Targeted tRF Therapeutics Triggers Ovarian Cancer Ferroptosis via Dual Inhibition of System Xc− 0.20
Potentiating Chemo-Immunotherapy via a Programmable Nanocapsule-Hydrogel Platform for Sequential Tumor Microenvironment Remodeling 0.28
Immuno-Packed T-Cell-Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment 0.08
Peptide Amphiphiles Hitchhike on Endogenous Biomolecules for Enhanced Cancer Imaging and Therapy 1.00
An Intracellular Magnetic Micromotor Drives Spatiotemporal Mechano‐Immunotherapy 0.04
Chemoselective Characterization of New Extracellular Matrix Deposition in Bioengineered Tumor Tissues 1.00
A Synergistic 3D-Printed Collar Transforms Radiofrequency Ablation Into Potent Thermal Immunotherapy for Lung Cancer 0.07
A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy 1.00
Photoinduced Plasmon Electron Transfer‐based Bioorthogonal Cleavage Reaction for Precision Tumor Therapy 0.09
Extracellular Matrix Topography Drives Adrenergic to Mesenchymal Transition in Neuroblastoma 0.83
1 0.84
Obesity promotes conserved inflammatory and metabolic transcriptional programs in colon tumors: Evidence from mouse models and the ColoCare Study patient cohort 0.84
5 4.12
Metabolomic profiling of genotype-derived ABO blood group, secretor status and Lewis antigens and association with pancreatic ductal adenocarcinoma risk 1.00
Body size and occupational physical activity during the life course and gastrointestinal cancers 0.47
Neighborhood racial and ethnic composition typology and breast cancer risk: the Multiethnic Cohort Study 1.00
Pre-diagnostic Body Mass Index Trajectories and Associations with Lung Cancer Risk 0.65
Guideline-based physical activity and health-related quality of life among prostate cancer survivors: a target trial emulation in the Health Professionals Follow-up Study 1.00
10 7.74
Ultra-rare functional variants reveal early-onset breast cancer risk genes and pathways in the UK Biobank and All of Us Research Program 1.00
An endothelial RNA splicing atlas catalogs effects of IL-1β and identifies an alternative PROCR isoform with genetic links to pleiotropic vascular disease 1.00
Bi-allelic loss-of-function variants in JKAMP cause a neurodevelopmental syndrome associated with dysregulation of GPR37 trafficking 0.07
Bi-allelic variants in neuronal adhesion molecule astrotactin 1 gene ASTN1 cause diverse neurodevelopmental disorders 0.47
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention 0.85
Origins and implications of intron retention quantitative trait loci in human tissues 1.00
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes 0.35
Genetic analysis in African ancestry populations reveals genetic contributors to lung cancer susceptibility 1.00
Saturation mapping of MUTYH variant effects using DNA repair reporters 1.00
Prioritizing disease-associated missense variants with chemoproteomic-detected amino acids 1.00
3 2.33
Comparing NIH Funding for Cancer Survivorship: A Spotlight on Breast and Gynecologic Cancer 1.00
Development and Validation of a Histology-Specific Natural History Model of Ovarian Cancer 1.00
Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II study 0.33
9 8.10
Characterizing the Discordance Between ARID1A Protein and Genotype in Endometrioid Type Endometrial Tumors 1.00
Apical enrichment of the RNAi machinery in oral stratified epithelia is disrupted in oral cancer 1.00
Spatially Resolved Obesity-Driven Molecular Changes in Early Breast Cancer 0.92
Epidermal Growth Factor Receptor/KIT-Linked Proliferative Bias in Normal Breast Lobules from Matched Non-Hispanic Black and White Women Is Rapidly Reversible by Receptor Tyrosine Kinase Inhibition 1.00
Ras Homolog Family Member V Promotes Pancreatic Ductal Adenocarcinoma Progression 0.91
Inhibiting the Secreted RGDKGE Collagen Peptide Selectively Controls CD8+ T-Cell Migration on Denatured Collagen-IV and Enhances Their Accumulation in Tumors 1.00
ADH1C downregulation is a key hypoxia response in colon epithelium 1.00
YAP AND TEAD ARE TRANSCRIPTIONAL REGULATORS OF NEUROENDOCRINE DIFFERENTIATION AND GROWTH IN CARCINOID CELLS 0.27
Activin A prevents hyper-responsiveness to VEGF in pathological blood vessels by perturbing the trafficking of activated VEGFR2 1.00
1 0.16
A trans-omics gene-smoking interaction study of lung cancer based on consortium data 0.16
5 2.44
High-Sensitive Spatial Proteomics for Pancreatic Cancer Progression Analysis 1.00
RamanMAE: Masked Autoencoders Enable Efficient Molecular Imaging by Learning Biologically Meaningful Spectral Representations 1.00
Assessing Acetyl-Coenzyme A Carboxylase Activity and Inhibition in iCaenorhabtidis elegans/i Using a Partially Purified Protein Extract 0.26
Deep Learning-Based Classification of NSCLC-Derived Extracellular Vesicles Using AFM Nanomechanical Signatures 0.13
Coupling Immunoprecipitation with Multiplexed Digital PCR for Cell-Free DNA Methylation Detection in Small Plasma Volumes of Early-Onset Colorectal Cancer 0.06
12 7.23
Marker‐Agnostic Tumor Anchoring Chimeras Enable pH‐Gated Immune Engagement 0.17
Reengineering Protease Inhibitors to Disrupt Hsp70 Chaperone Function 1.00
Smart Sonoafterglow Nanobombs for High‐Contrast Imaging and Synergistic Gas‐Sonodynamic Therapy of Hypoxic Tumors 0.10
GRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy 1.00
Neo‐Cysteine Molecular Glues for Targeting Mutated SMAD4 Protein 1.00
Discovery of a First-in-Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity 1.00
Esterase-Responsive Mitochondria-Targeted Hydropersulfide Donors Mitigate Doxorubicin Cardiotoxicity While Preserving Anticancer Activity 0.95
Superhydrophilic FeIV2MnII Nanocluster: A Combined Diagnostic and Therapeutic Agent 0.10
Naphthalimide-Based Type-I Nano-Photosensitizers for Enhanced Antitumor Photodynamic Therapy: H2S Synergistically Regulates PeT and Self-Assembly 0.08
Sulfinyl Aziridines as Stereoselective Covalent Destabilizing Degraders of the Oncogenic Transcription Factor MYC 0.87
Fragment‐Based Drug Discovery of Novel High‐affinity, Selective, and Anti‐inflammatory Inhibitors of the Keap1‐Nrf2 Protein‐Protein Interaction 0.17
Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death 0.80
1 1.00
Equity Evaluation of an Intervention to Increase Colorectal Cancer Screening at Federally Qualified Health Centers 1.00
5 4.73
Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations. 0.90
Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation. 1.00
Diagnostic Follow-up of Positive Results on Low-Dose Computed Tomography Screening in the Medicare Population. 1.00
Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups. 0.83
Effect of Personalized Risk Messages on Uptake of Colorectal Cancer Screening : A Randomized Controlled Trial. 1.00
1 0.25
Recombinant Human Neuregulin1‐β1 Significantly Reduces Schwannoma Growth in Mice 0.25
18 12.87
Pancreas Cancer Risk During Intraductal Papillary Mucinous Neoplasm Surveillance - A SEER-Based Comparison. 1.00
Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. 0.02
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.21
Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. 0.26
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.13
Elucidating the Optimal Use of Mitigation Strategies for Improving Pancreatic Fistula Rates after Pancreatoduodenectomy. 1.00
Accuracy of Flexible Sigmoidoscopy and MRI in Restaging Rectal Cancer after Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. 1.00
Implementation of Comprehensive Surgical Guidelines for Hepatoblastoma: Analysis of the Children's Oncology Group AHEP0731 Phase III Trial. 1.00
Population-Level Reduction in Ovarian Cancer Through Performance of Opportunistic Salpingectomy at the Time of Cholecystectomy. 1.00
Anatomic Location Predicts Response Rates: Real World Outcomes with Over 1,100 Cycles of Talimogene Laherparepvec (TVEC) Description: A Retrospective Review of a Prospectively Maintained Database. 1.00
Transitional Subtype of Circulating Tumor Cells in Early Post-Operative Period of 5-Year Survivors Following Resection of Pancreatic Ductal Adenocarcinoma. 1.00
International Validation of a Recurrence Risk Model for Stage II Colon Cancer: The SPHERE Study. 0.14
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer. 1.00
Clinical and Pathologic features of 535 Patients with Congenital Mesoblastic Nephroma: A Report from the Children's Oncology Group. 0.91
Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization For Unresectable Colorectal Liver Metastases. 1.00
The Organ-Specific Prognostic Value of TP53 Mutations in Pancreatic Cancer Patients with Oligometastasis Following Surgical Resection. 1.00
"I Just Wish Someone would Take me Very Seriously": Impact of Delayed Ventral Hernia Repair on Patient Wellbeing. 1.00
Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus. 0.19
1 0.92
High-intensity focused ultrasound (HIFU) based longitudinal shear wave elastography for tissue ablation planning 0.92
52 40.11
Antigen-boosted CD4CAR T cells fail to expand or control viremia in multiple nonhuman primate models of HIV 1.00
Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS 1.00
Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy 1.00
circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias 0.91
Inflammatory bowel disease–induced inflammation augments clonal hematopoiesis of indeterminate potential through Ref-1 0.97
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia 0.57
Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome 1.00
Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea 0.98
Immune biomarkers of increased infection risk in multiple myeloma 0.06
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma 0.92
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT 1.00
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability 0.95
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.13
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies 0.94
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy 1.00
Understanding how a highly prevalent GRK5 polymorphism affects platelets and enhances thrombotic risk 0.95
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) 0.89
Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08 0.98
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma 0.54
Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials 1.00
Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia 1.00
LRRC8 complexes are ATP release channels that regulate platelet activation and arterial thrombosis 0.98
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.56
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma 0.57
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL–mediated survival in myeloproliferative neoplasms 0.71
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia 0.93
Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma 0.98
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia 0.94
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results 0.19
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma 1.00
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.50
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.36
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up 1.00
CircFUT8 promotes proplatelet formation by interacting with IGF2BP2 and stabilizing TNS1 mRNA in megakaryocytes 0.08
Shear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosis 0.07
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.72
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma 0.90
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin 0.95
Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study 0.93
Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia 0.78
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of iJAK2/i-mutated post-MPN AML 0.92
Clinical presentation, management and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy 0.90
The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NFκB signaling 0.92
Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression 1.00
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion 0.04
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma 1.00
Restoring p53-wild type conformation in TP53-Y220C mutant acute myeloid leukemia 0.93
Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma 0.92
Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+ 0.90
Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome 0.06
Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors 1.00
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. 0.59
3 0.69
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease 0.25
De novo and inherited variants in DDX39B cause a novel neurodevelopmental syndrome 0.41
Deep learning analyses of splicing variants identify the link of PCP4 with amyotrophic lateral sclerosis 0.02
3 1.09
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.09
Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study 0.28
Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort study 0.72
40 28.24
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer 1.00
Whole-genome doubling drives immune evasion by silencing antigen presentation 1.00
Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer 1.00
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma 0.43
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study 0.04
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression 0.97
Molecular insights into early malignant transition of hepatocellular carcinoma 0.01
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors 1.00
Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer 1.00
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity 0.05
A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies 0.78
Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia 1.00
Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma 1.00
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence 0.99
Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression 1.00
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer 0.20
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma 0.03
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer 0.07
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition 0.69
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest 1.00
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors 1.00
Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma 1.00
Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches 1.00
Extrachromosomal DNA associates with nuclear condensates and reorganizes chromatin structures to enhance oncogenic transcription 1.00
Restraint of cancer cell plasticity by spatial homotypic clustering 0.97
Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer 1.00
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF metastatic colorectal cancer 1.00
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer 1.00
CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases 0.11
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma 1.00
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures 0.80
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer 0.03
Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer 1.00
Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy 0.67
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer 0.70
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression 0.58
A first-in-class EGFR-directed KRAS G12V selective inhibitor 1.00
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma 0.06
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer 0.98
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models 0.09
96 75.86
Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma 1.00
ARID1A Mediates SWI/SNF-Independent Maintenance of Heterochromatin Architecture to Restrain Viral Mimicry and Immunogenicity in Colon Cancer 0.13
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer 1.00
Loss of JAK1 Function Causes G2–M Cell-Cycle Defects Vulnerable to KIF18A Inhibition 0.95
Cell and Nuclear Size Is Associated with Chromosomal Instability and Tumorigenicity in Cancer Cells That Undergo Whole Genome Doubling 0.85
The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition 1.00
A MERTK-Targeting Antibody–Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells 1.00
ETC-501 Is a Brain-Penetrant MNK Inhibitor That Potentiates TMZ-Induced Senescence and Sensitizes Glioblastoma Cells to Senolytic Therapy 0.02
Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1 0.78
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment 1.00
Integrated Spatial Analysis Reveals the Molecular Landscape of Ovarian Precancerous Lesions 1.00
High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma 1.00
Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer 1.00
Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition 1.00
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules 0.46
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer 1.00
Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer 1.00
Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3′ Splice Sites in Cancer Progression 1.00
Comprehensive Multi-Omic Characterization of Perineural Invasion in Cervical Cancer Reveals Diagnostic Markers, Molecular Drivers, and Therapeutic Strategies 0.15
Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors 0.14
C-terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3 0.16
EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators 1.00
Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response 1.00
The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer 0.84
Integration of Short- and Long-Read RNA Sequencing Enables the Discovery of Circular RNAs 1.00
Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma 1.00
Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis 1.00
Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Anti-tumor Immunity 1.00
Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics 1.00
Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma 1.00
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma 0.57
Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma 0.13
An Olive Oil–Based High-Fat Diet Promotes Obesity-Driven Metastasis of Triple-Negative Breast Cancer 1.00
Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity 1.00
The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer 0.99
Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis 1.00
PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma 1.00
Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer 1.00
KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer 1.00
SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast Cancer 0.31
CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement. 0.09
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer. 1.00
Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma. 0.96
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. 1.00
Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment 1.00
MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer 1.00
KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma 0.03
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer 0.18
EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression. 1.00
The Aging Microenvironment is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer. 1.00
Enozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations. 0.81
In Silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response 0.28
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer. 1.00
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. 1.00
ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing Tumors. 1.00
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance 1.00
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. 0.96
Neoplastic Immune Mimicry Potentiates Breast Tumor Progression. 1.00
PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth. 0.90
Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation. 0.98
Metabolic Dependency on De Novo Pyrimidine Synthesis is a Targetable Vulnerability in Platinum Resistant Ovarian Cancer. 1.00
Radiation-Triggered Payload Release Enhances Bispecific Antibody Efficacy. 1.00
Wilm's Tumor 1-Expressing Stromal Cells Promote Pancreatic Cancer Progression. 0.97
Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer 0.07
PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers. 0.90
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer 0.94
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer 1.00
Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response 1.00
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma 1.00
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy 1.00
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy. 1.00
Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic Niche. 1.00
Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer. 0.06
The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma. 0.08
Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression. 1.00
HPV E5 Mediates Resistance to Chemotherapy and Radiation by Promoting a Stem Cell-Like Phenotype in Head and Neck Squamous Cell Carcinoma. 0.90
Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration Resistant Prostate Cancer. 1.00
Genome-Wide CRISPR Screening Reveals that mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer 0.88
PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m6A Methylation to Stabilize PARP1 mRNA. 0.17
Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer 0.89
Pancreatic Neuroendocrine Tumors Secrete Apolipoprotein E to Induce Tip Endothelial Cells That Remodel the Tumor–Stroma Ratio and Promote Cancer Progression 0.06
Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. 0.94
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy 0.18
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type 0.92
The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer 0.96
A Cyanobacteria-Derived RNA Aptamer Resensitizes Prostate Cancer to Hormone Therapy 1.00
HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data 0.75
The C-terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2 0.02
Spatial Profiling Identifies Regionally Distinct Microenvironments and Targetable Immunosuppressive Mechanisms in Pediatric Osteosarcoma Pulmonary Metastases 1.00
Single-Cell Expression Analysis of Ductal Carcinoma In Situ Identifies Complex Genotypic–Phenotypic Relationships Altering Epithelial Composition 1.00
Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation 0.29
Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors 1.00
NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma 1.00
Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy 1.00
FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development 1.00
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect 0.23
33 22.21
Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer 0.15
Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis 1.00
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers 0.03
Biodiversity and biogeography of the multi-kingdom cancer microbiome 0.50
Disrupted molecular glue complex drives RAS inhibitor resistance 1.00
ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging 1.00
Unbiased niche labeling maps immune-excluded niche in bone metastasis 1.00
Rational discovery of therapeutic PAK1 allosteric activators 0.05
Respiratory viral infections prime accelerated lung cancer growth 1.00
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias 0.05
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer 1.00
Fungal-derived cellobiose metabolic pathway fuels T cells to bypass intratumoral glucose competition 1.00
A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth suppression 1.00
Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial 0.85
Field-effect-informed urine liquid biopsy for bladder cancer 1.00
MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids 0.10
EcDNA-borne structural variants drive oncogenic fusion transcript amplification 0.93
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors 0.33
Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy 0.05
pTα enhances mRNA translation and potentiates CAR T cells for solid tumor eradication 1.00
Inhibition of oligomeric BAX by an anti-apoptotic dimer 0.90
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction 0.32
Creeping fat-derived mechanosensitive fibroblasts drive intestinal fibrosis in Crohn’s disease strictures 1.00
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers 0.25
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy 0.01
Vagal blockade of the brain-liver axis deters cancer-associated cachexia 0.74
Design of soluble Notch agonists that drive T cell development and boost immunity 0.96
DNA mutagenesis driven by transcription factor competition with mismatch repair 0.96
Regulation of inflammatory responses by pH-dependent transcriptional condensates 1.00
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma 0.99
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis 1.00
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis 0.03
MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma 1.00
2 0.99
Long-lasting gut microbiome and fecal metabolome alterations after colorectal adenoma removal and their relationship to colorectal cancer 0.87
Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections 0.13
6 4.99
Iron-addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death 0.99
Tissue and CD4 T cell subset dependence on the amino acid transporter SLC38A1 1.00
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML 0.05
Mitochondrial transfer from immune to tumor cells enables lymph node metastasis 1.00
Machine-learning-guided discovery of SLC25A45 as a mediator of mitochondrial methylated amino acid import and carnitine synthesis 1.00
OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis 0.95
8 5.24
Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML 0.03
Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells 0.02
Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease 1.00
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia 0.96
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy 0.75
TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice 0.83
Multiomic profiling reveals that prostaglandin E2 reverses aged muscle stem cell dysfunction, leading to increased regeneration and strength 1.00
HBO1 functions as an epigenetic barrier to hepatocyte plasticity and reprogramming during liver injury 0.66
2 2.00
A next-generation multimetal complex induces immunogenic cell death with distinct transcriptomic signatures 1.00
Therapeutic embolic agents for targeted drug delivery in transcatheter therapies: a review 1.00
2 1.81
Protein tyrosine phosphatase inactivation by electrophilic tyrosine modification 1.00
Light-triggered toll-like receptor activation in a nanoscale metal–organic framework for synergistic PDT and cancer immunotherapy 0.81
8 7.67
Linking Lungs and Heart 0.83
The 2021 US Preventive Services Task Force Lung Cancer Screening Criteria Miss Many Patients Diagnosed With Early and Late-Stage Lung Cancer 1.00
New and Growing Nodules Are Associated Strongly With Malignancy in Follow-Up Screening for Lung Cancer 0.83
Effectiveness of health communication intervention to improve knowledge on timeliness to return for annual lung cancer screening: The Larch Trial 1.00
Comparison of Underlying Risk of Developing and Dying from Lung Cancer in Screened Populations 1.00
Implementing a PREcision meDICine Thoracic (PREDICT) service using in-house reflex testing in a large academic-community practice 1.00
Association of Shared Decision-Making with Long-term Adherence to Lung Cancer Screening 1.00
Segmentectomy versus Lobectomy for Patients with 2-3cm Non-Small-Cell Lung Cancer 1.00
4 2.59
Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling. 1.00
Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. 0.78
Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension 0.05
miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. 0.76
2 2.00
Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001–2019 1.00
Clinical characteristics and survival of hospitalized anthrax patients with pleural, pericardial, or peritoneal fluid collections 1.00
1 1.00
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU. 1.00
3 3.00
A parent-of-origin effect on embryonic telomere elongation determines telomere length inheritance 1.00
Cohesin-mediated stabilization of the CCAN complex at kinetochores in mitosis 1.00
Spindle checkpoint can secure additional cheating time for selfish expanded centromeres 1.00
8 6.76
The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion 1.00
Disruption of WNT/Notch signaling in pancreatic cancer reveals tumors depend on the intricate equilibrium of malignant cell states 0.89
CircRNA-encoded RIPK1-98 protein drives lung adenocarcinoma progression 0.14
Ferroptosis induces heterogeneous death profiles that are controlled by lysosome rupture 0.81
Non-cell-autonomous tumor promotion in DICER1 cancer predisposition 1.00
Maternal CENP-C restores centromere symmetry in mammalian zygotes to ensure proper chromosome segregation 0.91
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer 1.00
AKT-mediated phosphorylation of TSC2 controls stimulus- and tissue-specific mTORC1 signaling and organ growth 1.00
1 0.83
Cigarette smoking and long-term incidence of colorectal cancer subclassified by tumor-infiltrating myeloid cells: A prospective cohort study 0.83
1 0.86
Effects of Residual PAH Exposure from Firefighters’ Skin and Turnout Gear on Biospecimen microRNA Expression 0.86
1 0.83
Mechanistic Insights into Adenovirus Resistance to UV: Dose-Dependent Repair and Delayed Suppression of Host DNA Damage Response 0.83
13 7.78
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer 0.97
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends 0.25
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry 0.02
Histopathology-based Artificial Intelligence Algorithms for the Prediction of Prostate Cancer Metastasis After Radical Prostatectomy 0.64
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial 0.19
Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems 1.00
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study 0.50
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder 0.86
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial 0.85
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer 1.00
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial 1.00
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial 0.20
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial 0.30
11 7.12
Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis 0.96
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial 0.14
Acinar Metaplastic Cells Generate Semi-Homogeneous Niches and Interact With Immune Cells 0.27
Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma 1.00
Depletion of Fibrinogen Suppresses Growth of Primary Tumors and Metastasis of Pancreatic Ductal Adenocarcinoma 0.87
An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study 0.03
Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 0.02
Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening 1.00
Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma 0.86
Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation 0.96
Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study 1.00
10 8.64
Bypass of blocking lesions by RNAPII reveals a novel stress induced by DNA damage 1.00
Multiomic analysis of clonal development reveals new regulators of leukemic cell growth 0.94
Separable roles for Microprocessor and its cofactors, ERH and SAFB1/2, during microRNA cluster assistance 0.60
Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems 0.17
Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer 0.93
The exon junction complex coordinates the cotranscriptional inclusion of blocks of neighboring exons 1.00
Leukemia mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness 1.00
SUMO2 promotes histone pre-mRNA processing by stabilizing histone locus body interactions and facilitating U7 snRNP assembly 1.00
Analysis of knockout mice reveals critical female-specific roles for the Hippo pathway component PTPN14 1.00
Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinoma 1.00
7 5.24
Dynamics of intronic polyadenylation in the hematopoietic lineage and its regulation by DNA methylation 1.00
Isoform- and pathway-specific regulation of post-transcriptional RNA processing in human cells 1.00
Confounding factors in assessing the enriched expression of somatic mutant allele in bulk tumor samples 1.00
Transcription and potential functions of a novel XIST isoform in male peripheral glia 1.00
APOBEC3A drives deaminase mutagenesis in human gastric epithelium 0.11
Alternative splicing generates HER2 isoform diversity underlying antibody–drug conjugate resistance in breast cancer 0.13
Endonucleolytic cleavage is the primary mechanism of decay elicited byiC. elegans/inonsense-mediated mRNA decay 1.00
13 4.35
<atl>iTff2/i marks gastric corpus progenitors that give rise to pyloric metaplasia/SPEM following injury</atl> 0.42
<atl>SLC6A14-mediated carnitine transmembrane uptake from PPARγ sup+/sup cancer-associated fibroblasts promotes recurrence of pancreatic cancer</atl> 0.15
Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening 0.13
Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics 0.54
Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition 0.10
Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial) 0.10
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy 0.01
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates iZFP36L2/i as a driver gene for pancreatic ductal adenocarcinoma 0.98
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.16
Gastrin-dependent expansion of Cck2r+ corpus progenitors accelerates ulcer healing and inhibits gastric dysplasia 0.73
Comparative risk of high-risk neoplasia after polypectomy among individuals aged below 50 years versus 50 years and older 0.82
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential 0.04
Hybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach 0.18
13 7.20
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.65
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma. 0.04
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria. 0.09
Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma. 0.52
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway. 0.10
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma. 0.47
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.28
FXR splicing by SF3B3 promotes MYC-driven hepatocarcinogenesis. 0.05
Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles. 1.00
Causes of mortality among patients with early-stage hepatocellular carcinoma. 1.00
Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma. 1.00
Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma. 1.00
Health information technology interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial. 1.00
8 6.58
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment 1.00
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.38
IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy 1.00
IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy 1.00
Gasdermin C cleavage by Cathepsin S modulates Rab7 vesicles in intestinal epithelial cells to amplify anti-helminth immunity 0.91
Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer 1.00
A fungal-derived adjuvant amplifies the antitumoral potency of Bacillus Calmette-Guérin via reprogramming granulopoiesis 0.30
Cellular mechanisms underlying beneficial versus detrimental effects of bacterial antitumor immunotherapy 1.00
2 0.69
An Evaluation of Cage Amine Sarcophagine Ligands for the Synthesis of Cobalt Radiopharmaceuticals 0.60
Macropa Scaffold Expansion for Actinium-225 Chelation: A Synthetic Strategy, Labeling Kinetics, and Theoretical Calculations 0.09
6 1.84
Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project 0.02
The impact of an organized screening program on gastric cancer incidence: a quasi-experimental study 0.21
Using Mendelian randomization to investigate etiologic heterogeneity across renal cell carcinoma subtypes 0.75
Investigating the association between anthropometry and colorectal cancer survival: a two-sample Mendelian randomization analysis 0.31
Body mass index and gastric cancer risk: results from the Stomach Cancer Pooling Project Consortium 0.21
Maternal prenatal infection and childhood leukaemia: a Childhood Cancer and Leukemia International Consortium (CLIC) meta-analysis 0.33
5 4.74
Mailed Outreach for Colorectal Cancer Screening in Community Health Centers 1.00
Palliative Care Intervention for Patients With End-Stage Liver Disease 1.00
Germline Pathogenic Variants Among Women Without a History of Breast Cancer 0.97
Frequent Missed Opportunities for Earlier Diagnosis of Advanced-Stage Colorectal or Lung Cancer 0.77
Patient Navigation Services for Breast and Cervical Cancer Screening and Follow-Up 1.00
12 8.45
Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2− Breast Cancer and Palpable Adenopathy 1.00
Immunotherapy Response in Microsatellite Instability–High Gastroesophageal Adenocarcinoma 1.00
An American College of Surgeons National Quality Improvement Collaborative to Enhance Lung Cancer Surgical Quality 1.00
AI–Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma 0.95
Locally Ablative Therapies in Oligometastatic Breast Cancer 1.00
Esophagectomy vs Active Surveillance in Clinical Complete Responders After Neoadjuvant Chemoradiation 0.19
International Reference Values for Surgical Outcomes of Total Pancreatectomy 0.20
Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status 1.00
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer 0.02
Gauging the Magnitude of Missed Opportunity for Ovarian Cancer Prevention 1.00
Exosomal Liquid Biopsy for the Early Detection of Gastric Cancer 0.15
Long-Term Locoregional Outcomes in a Contemporary Cohort of Young Women With Breast Cancer 0.93
9 7.33
Cancer Diagnostic Delay Rates Associated With a Population-Based Screening Trial Evaluating a Cell-Free DNA Multicancer Early Detection Test. 0.80
Biomarker-Based Eligibility for Lung Cancer Screening: Validation of the Protein-Based INTEGRAL-Risk Model. 0.47
Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy 1.00
A Lay Health Worker–Led Symptom Intervention and Acute Care Use in Older Adults With Cancer 1.00
Risk-Based vs Annual Breast Cancer Screening 0.97
A Direct-to-Patient Digital Health Program for Lung Cancer Screening 1.00
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis 0.08
Population Health Colorectal Cancer Screening Strategies in Adults Aged 45 to 49 Years 1.00
Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer 1.00
84 70.49
Dysregulated HELLS expression alters cellular processes and serves as a potential prognostic marker in acute myeloid leukemia 0.14
Clinically observed RASA1 missense mutants exhibit diverse RasGAP protein behaviors in vitro 1.00
Reciprocal compensation of caspase-2 and p53 regulates the DNA damage response in HCT116 colon cancer cells 1.00
Pontocerebellar Hypoplasia linked mutations of the deadenylase Target of EGR1 (TOE1) impair thermal stability, ribonuclease activity, and oligomerization 0.78
A tri-specific EGFR/cMet/VEGF antibody demonstrates potent multi-mechanistic activity in preclinical triple-negative breast cancer models 0.07
Structure and enzymology of glutaminase S482C and H461L variants associated with excess brain glutamate and neurological disease 1.00
An inhibitor of GCN2 and the integrated stress response directly targets ZAK protein kinase to limit cytotoxicity 1.00
Genome-wide chromatin profiling reveals a nonlimiting role for RXR in macrophage-like cells stimulated with multiple nuclear receptor agonists 0.05
Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects 0.85
The E3 ligase β-TRCP1 earmarks OTUD3 for destruction to fine-tune cGAS activation 1.00
PRSS23 promotes ovarian cancer peritoneal dissemination independent of protease activity 0.80
Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition 1.00
Modulation of the stress-activated protein kinases Hog1/p38 and a TORC1-dependent kinase by curcumin is stress granule-dependent 1.00
Crystal structure of RohS, a heme-oxygenase-like N-oxygenase from azomycin biosynthesis 0.13
Mesothelin Promotes Acute Myeloid Leukemia Progression through LYN-dependent Signaling 1.00
CircNOLC1/KRT16 Promotes Colorectal Cancer Invasion and Migration via c-Met Nuclear Translocation and Reprogramming of the Oxidative Pentose Phosphate Pathway 0.05
Siah2 Regulates Lipid Uptake in Adipose Tissue Macrophages 1.00
The Dual-specificity Phosphatase JSP1 Regulates Neutrophil Adhesion via Integrin-SRC Signaling in Vascular Inflammation 1.00
Labile iron pool dynamics do not drive ferroptosis in colorectal cancer cells 1.00
AKAP2 is required for assembly of cytoskeletal signaling complexes that promote growth and metastasis of triple-negative breast cancer 1.00
An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates 0.82
Altered benzo[a]pyrene adduct formation in nucleosomes establishes distinct mutational patterns in lung cancer 0.50
The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma 1.00
HSP-1-Specific Nanobodies Alter Chaperone Function in vitro and in vivo 0.77
KRAS4a and KRAS4b show distinct lipid-dependent regulation of RAS-RAF membrane dynamics 1.00
Engineering an orthogonal ubiquitin transfer cascade with Ring E3 RNF38 by phage display to reveal its regulation of nuclear transport 0.89
Inhibition of cell surface GRP78 on brain tumors reverses drug resistance and stops cancer stem cell expansion 1.00
Biochemical Analysis of a TrkB Receptor Mutation that Causes a Developmental Epileptic Encephalopathy 1.00
Intracellular pH regulates β-catenin with low pHi increasing adhesion and signaling functions 1.00
Ser500 phosphorylation acts as a conformational switch to prime eEF-2K for activation 1.00
Mitotic chromatin compaction tethers extrachromosomal DNA to chromosomes and prevents their mis-segregation into micronuclei 1.00
Structural Basis for Substrate Recruitment and Catalytic Ubiquitin Transfer by the E2/E3 Hybrid Enzyme UBE2O. 0.04
IGFBP-6 Regulates Breast Cancer Cell Cycle Progression by Promoting Exit Out of G1 1.00
A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F 0.33
KRASG12D mutation promotes pancreatic tumorigenesis by suppressing sirtuin three via the guanine nucleotide exchange factor RCC1 0.13
Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma 1.00
Targeting the protein–protein interaction between the CDC37 cochaperone and client kinases by an allosteric RAF dimer breaker 1.00
The mitotic functions of a fission yeast CK1 enzyme are regulated by Cdk1-dependent and auto-phosphorylation 1.00
Triglyceride lipase PNPLA2-independent suppression of c-MYC signaling by the metabolic coactivator ABHD5 in prostate cancer 1.00
Cholesterol promotes the formation of dimers and oligomers of the receptor tyrosine kinase ROR1 0.57
Nuclear VAV1 increases GLI1-dependent transcription in pancreatic cancer cells 1.00
An evolutionary T119R substitution in the macaque T-cell immunoreceptor TIGIT enables proteolytic shedding and reveals clinical antibody vulnerabilities 1.00
Adenovirus E4ORF1 activates isoform-specific phosphatidylinositol 3-kinase signaling 0.97
A Modular Uba1-Nanobody Fusion Enables Selective Ubiquitin Transfer to Tagged E2 Enzymes 0.42
Auxin-Induced Depletion of Human CCR4-NOT Subunits Reveals Opposing Functions of CNOT1 and CNOT4 in mRNA Metabolism 1.00
Structures of human protein tyrosine phosphatase variants reveal targetable allosteric sites 0.50
Mutagenesis of the PALB2 WD40 domain identifies variants defective in interaction with BRCA2 and DNA repair 0.29
Characterization and inhibitor sensitivity of ARAF, BRAF, and CRAF kinases 1.00
RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis 1.00
Sirtuin 6 is a histone delactylase 1.00
Rules of engagement: Determinants of chemokine receptor activation and selectivity by CCL27 and CCL28 0.92
Inhibition of HDAC7 reprograms the histone H3.3 landscape to induce heterochromatin spreading and DNA replication defects in cancer cells 1.00
BATF2-mediated control of astrocyte proliferation 1.00
NR4A1 is a HIF-dependent repressor of SLC30A10 transcription that controls manganese homeostasis 1.00
Defined media reveal the essential role of lipid scavenging in supporting cancer cell proliferation 1.00
Functional dissection of the zDHHC palmitoyltransferase 5–golgin A7 palmitoylation complex 1.00
Biochemical reconstitution of temozolomide-induced mutational processes 1.00
Activity-based probes and chemical proteomics uncover the biological impact of targeting HMG-CoA Synthase 1 in the mevalonate pathway 1.00
Dissecting the Cdc37 cochaperone code: Functional roles in chaperone-mediated stress adaptation 1.00
Ciprofloxacin enhances RSL3-induced ferroptosis by promoting mitochondrial Zn2+ accumulation via the STING1–CAV2 pathway 0.22
Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism 0.93
The critical role of the C-terminal lobe of calmodulin in activating eukaryotic elongation factor 2 kinase 0.95
Class I histone deacetylases catalyze lysine lactylation 1.00
Type I gamma phosphatidylinositol phosphate kinase i5 suppresses YAP1 signaling 1.00
The molecular mechanism of ambrosin-induced cytotoxicity of human breast cancer and bladder cancer cells 0.98
The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma 1.00
ERK signaling promotes IKKε expression and oncogenic functions in pancreatic cancer cells in association with TBK1 1.00
Cytochrome P450 2W1: Identification of New Inhibitors, Active Site Ligands, and Pharmacophores 1.00
Metabolomics analysis of SNAT2-deficient cells: Implications for the discovery of selective small-molecule inhibitors of an amino acid transporter 0.33
The U1 snRNP-specific protein U1C is a key regulator of SMN complex–mediated snRNP formation 1.00
A novel protein encoded by circTUBGCP3 blocks ferroptosis and promotes gastric cancer progression 0.08
Development of novel mitochondrial pyruvate carrier inhibitors for breast cancer treatment 1.00
The ubiquitin ligase Triad1 influences myeloid leukemogenesis by regulating the integrated stress response 1.00
Paracrine regulation of pancreatic cancer cell response to chemotherapy by GLI2-Collagen I signaling 1.00
Restricted Human CD45 Isoglycoforms Serve as Functional E-selectin Ligands and Delineate Hematopoietic Maturity 1.00
PLK1-mediated PDHA1 phosphorylation drives mitochondrial dysfunction, mitophagy, and cancer progression in Cr(VI)-associated lung cancer 1.00
HSD3B1 Upregulation via LRH1 Sustains Estrogen Receptor Signaling and Promotes Endocrine Resistance in Breast Cancer 1.00
5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells 1.00
Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations 1.00
Regulation of NRF2 by stably associated phosphoinositides and small heat shock proteins in response to stress 1.00
BET bromodomain inhibitors attenuate transcription of a subset of IL-1-induced NF-κB targets that promote inflammation in β-cells 1.00
Select early growth response (Egr) isoforms augment hypoxia inducible factor 2 (HIF-2) regulation of erythropoietin (Epo) gene expression in mammals 1.00
Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints 1.00
Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions 1.00
4 2.87
Effect of Timing of First Consultation with a Sarcoma Specialist Following Unplanned Excision: Oncologic Outcomes of Patients with Soft-Tissue Sarcomas. 0.71
The Cost-Effectiveness of Enoxaparin Compared with Aspirin for Thromboprophylaxis in Patients with Orthopaedic Trauma. 1.00
Trends and Impact of Pharmacological VTE Prophylaxis Timing for Traumatic Cervical Spinal Cord Injury Across North American Trauma Centers 0.15
Postoperative Clopidogrel Thromboprophylaxis in TJA: Increased Risk of Transfusion but Similar Venous Thromboembolic Risk Compared with Aspirin. 1.00
14 11.26
Tetraspanin CD82 shapes EGFR signaling outcomes through nanoscale receptor organization 1.00
Cullin-3 adaptor SHKBP1 inhibits SQSTM1/p62 oligomerization and Keap1 sequestration 1.00
DUX4-induced HSATII RNA accumulation drives protein aggregation, impacting RNA processing pathways 1.00
Anaphase onset requires CKS-1–mediated destruction of securin in meiosis I and cyclin B1 in meiosis II 1.00
Mechanical coordination between anaphase A and B drives asymmetric chromosome segregation 0.21
Moesin controls cell–cell fusion and osteoclast function 0.15
Origin of chromosome 12 trisomy surge in human induced pluripotent stem cells 1.00
Telomeric SUMO level influences the choices of APB formation pathways and ALT efficiency 0.83
A coordinated kinase and phosphatase network regulates Stu2 recruitment to yeast kinetochores 1.00
Spindle morphology changes between meiosis and mitosis driven by CK2 regulation of the Ran pathway 1.00
The Unkempt RNA-binding protein reveals a local translation program in centriole overduplication 1.00
The PAX3-FOXO1 fusion gene reduces cell–ECM interactions and TGFβ signaling in rhabdomyosarcoma 1.00
MTMR regulates KRAS function by controlling plasma membrane levels of phospholipids 1.00
Plasticity of mitotic cyclins in promoting the G2–M transition 0.06
10 8.34
Time trends in incidence, treatment, and survival of patients with adrenocortical carcinoma, a nationwide study 0.06
Age-specific risk of malignancy in pediatric thyroid cytology: Reframing ROM based on pre-test probability 0.27
Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules 1.00
Utility of genomic sequencing classifier in managing cytologically indeterminate oncocytic thyroid nodules 1.00
Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific and Neo-antigens in Follicular Cell-derived Thyroid Cancers 1.00
Determining Thyroid Biopsy Appropriateness: A Retrospective Study Integrating Clinical Context and Ultrasound Features 1.00
Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients 1.00
Long-Term Outcomes of Patients Diagnosed With Differentiated Thyroid Cancer in Childhood and Young Adulthood 1.00
Long-term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model 1.00
Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues 1.00
92 73.91
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters 1.00
Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model 0.03
IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis 0.08
Iron overload in steatotic hepatocytes drives systemic metabolic dysfunction via alterations in hepatokine production 0.09
Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models 1.00
Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guérin vaccine in High-Risk Bladder Cancer 1.00
Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy 1.00
Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancer 1.00
Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance 1.00
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers 0.13
Genome-wide CRISPR screen identifies a cytokine–enhancer circuit driving HIF-2α activation in renal cancer 0.88
CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models 1.00
Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models 1.00
Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity 0.94
Inhibiting LSD1 unlocks retinoid AP-1 programming to activate epithelial immunity and skin tumor suppression 1.00
A therapeutic role for a regulatory glucose transporter1 (GLUT1)-associated lncRNA in GLUT1-deficient mice 1.00
IFN signaling is associated with radiotherapy response in malignant peripheral nerve sheath tumors 1.00
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model 1.00
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models 0.69
ER-associated degradation pathway protein SEL1L plays an evolutionarily conserved role in platelet adhesion 0.71
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma 0.06
Alternative splicing-triggered mRNA decay informs splice-switching targets for neurodevelopmental disorders 1.00
Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma 1.00
Targeting Pim2 Improves Antitumor Immunity through Promoting Effector Function and Persistence of CD8 T cells 1.00
Rho/ROCK signaling and α-Catenin mediate β-Catenin-driven hyperplasia in the adrenal cortex via adherens junctions 0.89
Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation 0.05
ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming 1.00
Reversing enhancer RNA–mediated IKBKE gene repression enables synthetic anticancer immunity in prostate cancer models 0.49
Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirements 1.00
FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome 0.97
Glioblastoma stem cells resist cuproptosis with circadian variation of copper levels 1.00
NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress 1.00
Mitochondrial Oxidants Promote Platelet Activation and Thrombotic Susceptibility in Prediabetes 1.00
Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models 1.00
MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype 1.00
PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation 1.00
Interlocking host and viral cis-regulatory networks drive Merkel cell carcinoma 1.00
Targeting kinesin family member 20A sensitizes stem-like triple-negative breast cancer cells to standard chemotherapy 0.95
Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation 1.00
CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer 0.85
Osimertinib activates a TGFβ2-dependent secretory program that drives lung adenocarcinoma progression 1.00
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression 0.06
Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer 0.35
Estrogen Receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer 0.09
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I 0.89
Curing autoimmune diabetes in mice with islet and hematopoietic cell transplantation after CD117 antibody-based conditioning 1.00
GSK3B directs DNA repair choice and determines tumor response to PARP1 inhibition independent of BRCA1 1.00
Allosteric modulation of the solute carrier transporter SLC39A8 potentiates manganese and cadmium uptake 1.00
IFN-γ–driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy 0.95
T-cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges 0.81
RCC2 and CD24 cooperate to modulate prostate cancer progression through vimentin ubiquitination and β-catenin activation 1.00
A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer 1.00
Kidney-specific claudin-2 deficiency leads to medullary nephrocalcinosis in mice 1.00
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion 0.95
SOX9 drives a stem-like transcriptional state and platinum resistance in high-grade serous ovarian cancer 1.00
CTLA-4 blockade shifts the B cell repertoire towards autoimmunity 1.00
Acetyl-CoA carboxylase-1 inhibition increases regulatory T-Cell metabolism and graft-vs-host disease treatment efficacy via mitochondrial fusion 0.83
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose 0.71
USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer 0.08
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia 0.16
Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis 1.00
Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology 1.00
The functionally conserved human lncRNA motif GULF lowers glucose and lipid levels in obese mice 1.00
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models 0.18
ZEB1 promotes chemo-immune resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16 0.15
A smooth muscle cell lncRNA controls angiogenesis in chronic limb-threatening ischemia through miR-143-3p/HHIP signaling 0.88
SEC61B regulates calcium flux and platelet hyperreactivity in diabetes 0.06
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer 0.33
A distinct mechanism of epigenetic reprogramming silences PAX2 and initiates endometrial carcinogenesis 0.95
Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models 1.00
Overexpression of the signaling-coordinator GAB2 can play an important role in Acute Myeloid Leukemia progression 1.00
CBFβ-SMMHC–driven leukemogenesis requires enhanced RUNX1-DNA binding affinity in mice 1.00
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy 1.00
Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma 0.98
Inverted chimeric RNAi molecules synergistically co-target MYC and KRAS in KRAS-driven cancers 1.00
First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors 1.00
HIF-1 promotes murine breast cancer brain metastasis by increasing production of integrin β3–containing extracellular vesicles 1.00
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade 1.00
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING 1.00
Mutations in spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly 0.23
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma 1.00
A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/– mice 0.97
Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop 0.47
BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature-positive castration-resistant prostate cancer 0.90
Nemo-like kinase disrupts nuclear import and drives TDP43 mislocalization in ALS 1.00
Inhibiting inflammation in adipocytes accelerates mammary tumor development in mice 0.90
RSK1-driven TRIM28/E2F1 feedback loop promotes castration-resistant prostate cancer progression 1.00
TNF-α impairs platelet function by inhibiting autophagy and disrupting metabolism via syntaxin 17 downregulation 0.87
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer 1.00
CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors 0.54
TDP-43 dysregulation of polyadenylation site selection is a defining feature of RNA misprocessing in amyotrophic lateral sclerosis and frontotemporal dementia 0.98
PROX1 is an early driver of lineage plasticity in prostate cancer 0.84
75 41.95
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial 1.00
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.35
Concurrent versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of “High Risk” Early Breast Cancer: NRG/RTOG 1005 Phase III Trial 0.88
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. 0.93
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). 1.00
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. 0.69
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.43
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. 0.62
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. 0.94
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. 0.03
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. 0.55
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. 0.94
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. 1.00
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. 0.42
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study. 0.06
Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups. 1.00
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2. 0.29
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer. 0.83
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. 0.63
Integrating Electronic Patient-Reported Outcomes and Palliative Care in Pediatric Advanced Cancer: The PediQUEST Response Multisite Randomized Controlled Trial. 0.75
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147). 1.00
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. 1.00
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II). 0.25
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study 0.06
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. 0.62
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study. 0.24
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. 0.96
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. 1.00
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma. 0.93
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. 1.00
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. 0.04
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.18
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.36
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.55
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. 0.72
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.44
Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533. 0.89
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. 0.18
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. 0.16
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial. 0.44
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. 0.27
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report. 0.79
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. 1.00
Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. 0.92
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.68
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. 0.42
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.13
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. 0.14
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.25
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay. 0.08
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. 0.10
Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study. 1.00
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. 0.03
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. 0.84
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. 1.00
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.61
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study. 0.07
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 0.20
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.19
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. 0.60
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). 0.59
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. 0.03
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. 0.58
Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation. 1.00
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. 1.00
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. 1.00
Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma. 1.00
Mindfulness and Tai Chi for Cancer Health (MATCH) Study: Primary Outcomes of a Preference-Based Multisite Randomized Comparative Effectiveness Trial. 0.13
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. 1.00
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.16
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. 0.15
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. 0.44
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. 0.63
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. 0.23
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.36
12 11.15
Targeting conserved domains of hypoxia-inducible factors for cancer therapy 1.00
Defects in intron recycling suppress the antiviral response via a mechanism of intronic endogenous dsRNA 0.81
Liver-X-receptor agonism enhances T cell priming and activation to promote anti-tumor immunity 0.76
HIF-1–mediated ISG20 expression promotes breast cancer stemness and immune evasion 0.96
SLC7A8 is essential for metabolic fitness and function of Th2 cells 1.00
Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function 0.92
PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion 1.00
Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma 0.95
Histidine decarboxylase inhibition attenuates cancer-associated muscle wasting 1.00
Sympathetic axonogenesis promotes adenoid cystic carcinoma progression 0.75
Tumor cell heterogeneity drives spatial organization of the intratumoral immune response 1.00
Dominant interfering CARD11 variants disrupt JNK signaling to promote GATA3 expression in T cells 1.00
9 5.14
Global patterns of mutational profiles in biliary tract cancer 1.00
Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression 0.49
Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma 1.00
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma 0.46
MARCO+ macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis 0.07
HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort 1.00
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma 0.54
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma 0.56
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 0.02
4 3.36
Enterotoxigenic Bacteroides fragilis Induces Host Genotype-Specific Colonic Epithelial and Immune Responses in Mice 1.00
Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy–Suppressed Viral Load 1.00
Safety, immunovirological, and CNS effects of PD-1 inhibition in people with HIV without malignancy 1.00
Profiling Human Papillomavirus Lineage-Specific Capsid Antigenicity With Geographically Diverse Natural Infection Antibodies 0.36
4 3.80
Cell-intrinsic regulation of epilepsy-associated pathology by mTORC1 and mTORC2 1.00
Ubiquitin Proteasome System Components, RAD23A and USP13, Modulate TDP-43 Solubility and Neuronal Toxicity 1.00
Cofilin inhibition ameliorates PIEZO2 and AMPA dysfunction in a mouse model of Angelman syndrome 1.00
Neddylation E1 obligatory subunit Nae1 is critical to neuromuscular junction development and maintenance 0.80
1 0.75
Effects of inhibition of Janus kinase signalling during controlled mechanical ventilation on the rate of skeletal muscle protein synthesis 0.75
17 15.41
Neoadjuvant Chemoradiation versus Perioperative Chemotherapy in Locally Advanced Resectable Esophageal Adenocarcinoma: A National Analysis 1.00
Prospectively Screening for Venous Thromboembolism in Patients with Esophagectomy for Cancer Improves Survival: The Complexity of Simplicity 1.00
Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non–small cell lung cancer 0.95
Lobectomy improves disease-free survival over sublobar resection for high-risk stage IA non−small cell lung cancer 1.00
Diagnostic yield of routine frozen section pathology examination of lymph nodes in lung resections for clinical stage IA non–small cell lung cancer 1.00
Image-guided radiofrequency ablation for treatment of stage I non–small cell lung cancer in 111 high-risk patients: Analysis of prognostic variables 1.00
Characterizing phantom lymph node collection during curative-intent resection of non−small cell lung cancer 0.95
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer 0.36
Extent of resection for spread-through air spaces−positive stage IA1-2 non−small cell lung cancer 1.00
Surgical Outcomes Using Three-Dimensional Image Simulation for Segmentectomy Planning in Patients with Stage IA1-2 Non-Small Cell Lung Cancer 1.00
Neoadjuvant nonablative stereotactic body radiotherapy plus immunotherapy yields similar pathologic response as chemoimmunotherapy in non–small cell lung cancer 1.00
The Association of Short-Term Outcomes and Long-Term Survival After Lung Cancer Resection 1.00
Association of chemoradiation, trimodality therapy, or salvage resection with survival in stage II-III esophageal squamous cell carcinoma 1.00
Early compliance with lung cancer lymph node standard 5.8: An analysis of 2022 and 2023 Commission on Cancer site reviews 1.00
Incidental use of angiotensin system inhibitors during neoadjuvant therapy for esophageal adenocarcinoma: An analysis of survival 0.83
Extent of resection in surgically resected stage IV non−small cell lung cancer: Results from two tertiary referral centers 0.71
The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: results from CALGB 140503 (Alliance) 0.60
7 6.00
Health disparities in narrowband UVB phototherapy for mycosis fungoides: A multi-institutional cohort study across Fitzpatrick skin types 1.00
Validation of PARACELSUS score performance for the diagnosis of pyoderma gangrenosum: An international multicenter study with 1403 cases 0.20
Long-term outcomes in juvenile-onset mycosis fungoides 1.00
Population differences in Merkel cell carcinoma by virus status and anatomic site: A multi-cohort analysis including institutional, SEER, and NCDB data 1.00
Impact of Disease Stage, Treatment Timing, and Demographic Disparities on Survival in Vulvar Squamous Cell Carcinoma: Insights from a SEER-Based Analysis 1.00
Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study 0.80
Disparities in Acral Lentiginous Melanoma: Racial Factors Beyond Delayed Diagnosis 1.00
25 19.02
Polyoxometalate-Assisted Crystallization: A General Strategy Enabling Structural Characterization of Molecular Radium Complexes 1.00
Manganese-Templated Nontrivial Structures for MRI and Therapy 0.20
Discovering Targetable Conformation of RhoA Mutant by Integrating Native Mass Spectrometry, Ultraviolet Photodissociation, and X-ray Diffraction 0.03
Sprayable Lactococcus lactis-Nanocatalyst Gel for Postsurgical Immunomodulation in Preclinical Oral Squamous Cell Carcinoma 0.83
Spatial Confinement of Platinum Nanoclusters in a Photoactive Metal–Organic Framework for Radiotherapy Enhancement and Redox-Mediated Immune Activation 0.94
Modulation of the 14-3-3σ/C-RAF “Auto”inhibited Complex by Molecular Glues 0.53
Design and Development of DNA Damage Chemical Inducers of Proximity for Targeted Cancer Therapy 1.00
Synthesis and Structural Confirmation of Secalosides A and B 1.00
Rewiring the Fusion Oncoprotein EWSR1::FLI1 in Ewing Sarcoma with Bivalent Small Molecules 1.00
A Sterically Open Ruthenium-Based Photocage Activated by Red and Far-Red Light for a Wide Range of Drugs 0.27
Exploiting Metabolic Vulnerabilities in Cancer with a Dual-Transporter-Targeted 2-Deoxyglucose Analogue for Low-Dose, Potent Antitumor Activity 1.00
Hijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery 1.00
The Allosteric Regulator Inositol Phosphate Dramatically Affects the Efficacy and Selectivity of Inhibitors for Different HDAC Complexes 0.17
Structure over States: Planarity, Not Energy, Dictates Photoactivation in Ru(II) PACT Agents 0.14
Cytochrome P450 Induction through the Efficient Photoinduced Release of a Pyridine-Substituted Agent from Ru(II) 1.00
An Alkyne-Directed Cleavage Approach for Activity-Based Cu(I) Sensing Reveals Manganese-Promoted Sensitization of Cuproptosis 1.00
Photoaffinity Labeling Reveals a Role for the Unusual Triply Acylated Phospholipid N-Acylphosphatidylethanolamine in Lactate Homeostasis 1.00
Overcoming Immune Checkpoint Inhibitor Resistance with Potent, Selective Dual αvβ6/8 Inhibitors Based on Engineered Lasso Peptides 1.00
Deubiquitinase-Targeting Chimeras Mediated Stabilization of Tumor Suppressive E3 Ligase Proteins as a Strategy for Cancer Therapy 1.00
Structural Basis for Oxidized Glutathione Recognition by Yeast Cadmium Factor 1 1.00
Nanoscale Donor–Acceptor Covalent Organic Frameworks for Mitochondria-Targeted Sonodynamic Therapy and Antitumor Immunity 1.00
Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells 1.00
Long-Lived Immunogenic Cell Death Induced by a Water-Soluble Redox Active Au(I) Bis-N-Heterocyclic Carbene 0.83
Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer 0.07
Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells 1.00
5 4.93
Association of Hospice Accreditation With Quality Measures 1.00
Trends in Hospice Use Among Older Adults With Dementia and Cancer by Race and Ethnicity 2011–2021 0.93
Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission 1.00
Mammography Completion by Age Among Women in the Veterans Health Administration 1.00
Few Older Women Are Aware of Guidelines on When to Stop Breast Cancer Screening 1.00
79 60.58
Belzutifan Efficacy in Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma Versus Natural History Control Arm 1.00
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial 0.07
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid Tumors 0.08
Differences in breast cancer survival across Asian American ethnicities compared with non-Latina White females in Kaiser Permanente Northern California 1.00
Performance of clinical breast cancer risk prediction models versus a mammography-based artificial intelligence risk model 1.00
Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium 0.54
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes 1.00
Methylation signatures distinguish non small cell lung cancer subtypes and associated with survival in smokers with lung squamous cell carcinoma 1.00
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer 1.00
CRC-SPIN version 3.0: an updated policy model for colorectal cancer screening that includes the serrated pathway 1.00
Sex-based prognosis in industry-sponsored advanced solid tumour trials: an individual participant data meta-analysis of survival and adverse events 0.19
Identifying expression and DNA methylation biomarkers for lung adenocarcinoma risk in East Asia 0.23
Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study 0.59
Postpartum breast cancer: evidence for a distinct phenotype 0.96
A smoking-related plasma protein score and smoking-related cancer risk and mortality in ARIC 0.63
Sex steroid hormones, gonadotropins, and risk of testicular germ cell tumors: results from the STEED study 0.94
Addressing algorithmic bias in lung cancer screening eligibility 1.00
<atl>Impact of iKRAS/i codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab</atl> 0.89
Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment 0.08
Second primary cancer in breast cancer survivors by race/ethnicity and asian subgroups: a descriptive epidemiologic study 1.00
Walking dose associated with lower cancer-related fatigue among patients with breast cancer 1.00
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer 0.94
Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation 1.00
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience 0.96
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer 0.94
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.82
Unmet social needs and colorectal cancer testing at 45-49 since the 2021 USPSTF recommendation 1.00
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials 0.52
Personalizing lung cancer screening recommendations for heterogenous populations: a microsimulation study 0.86
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer 1.00
Time-dependent relationship between urinary biomarkers of nucleic acid oxidation and colorectal cancer risk 0.92
Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial 0.13
Trends and Projected Burden of Early-Onset Gastrointestinal Malignancies in the United States: A Population-Based Analysis (2001–2021) 1.00
Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer 0.12
Frequency and clinical features of germline pathogenic variants in sarcoma: a case-control study 0.97
Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030) 1.00
Comparative benefits, burdens and harms of emerging blood-based tests for colorectal cancer screening 1.00
Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies 1.00
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.29
Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers 1.00
Survivorship care and mortality in a contemporary and diverse cohort of childhood cancer survivors 1.00
Diagnostic yield of surveillance mammography among older women 1.00
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance) 0.94
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.30
Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer 0.65
Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study 1.00
Gaps in care across the cancer screening continuum for cervical, colorectal, and lung cancers 1.00
Germline rare variants in cancer susceptibility genes and subsequent neoplasm risk after childhood cancer 1.00
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma 0.32
Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer 0.89
The impact of eligibility criteria on KRASG12C inhibitor trials in patients with NSCLC 1.00
Mortality after colorectal cancer among survivors of childhood cancer 0.88
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort 1.00
Impact of daily adaptive head and neck radiotherapy on toxicity and quality of life: results of the DARTBOARD phase II randomized trial 1.00
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer 0.92
Active surveillance for low-risk prostate cancer: long-term utilization and outcomes among Black men 1.00
Survival deficits in young women with breast cancer in sub-Saharan Africa: the African Breast Cancer–Disparities in Outcomes cohort 0.08
Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021 0.67
A prediction model for metachronous colorectal cancer: development and validation 0.20
Aprepitant use during chemotherapy and association with survival in women with early breast cancer 0.02
Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods 1.00
Incidence of rare cancers during the COVID-19 pandemic: a US population-based study 1.00
Clonal hematopoiesis and risk of non-myeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation 1.00
Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC 0.65
Trends in young-onset cancer incidence: a modeling perspective 1.00
Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors 1.00
Determinants of late metastases in renal cell carcinoma 1.00
Breastfeeding after breast cancer in young iBRCA/i carriers 0.07
The association between clinical trial participation, drug costs, and performance in the Oncology Care Model 1.00
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.03
Expected versus observed effect sizes for survival endpoints in phase 3 oncology trials 1.00
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer 0.18
Clonal hematopoiesis and subsequent venous thromboembolism among survivors of autologous transplantation for lymphoma 1.00
Trends in uterine cancer incidence and mortality: insights from a natural history model 1.00
Cardiometabolic outcomes after bariatric surgery in adult survivors of childhood cancer: a St Jude Lifetime Cohort report 0.93
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults 0.25
Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females 1.00
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma 0.99
Following the American Cancer Society guideline for cancer survivors and obesity-related cancer survival 1.00
1 0.46
Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy 0.46
27 21.59
PARP1 suppression drives ROS resistance in aneuploid cancer cells 1.00
A time-resolved atlas of histone modifications during mitotic entry 0.15
mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway 1.00
MRE11 proximal polyadenylation site-mediated looping impacts transcription and genomic stability 0.82
BRCA2-dependent maturation of nascent strands during DNA replication 0.13
U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAs 1.00
The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic cancer 1.00
ER-tethering directs TREX1 penetration of a BAF-dependent barrier at micronuclei 0.85
LncRNA-splicing factor condensates regulate hypoxia-responsive pre-mRNA processing near nuclear speckles 1.00
LENG8 mediates RNA nuclear retention and degradation in eukaryotes 1.00
Splice-switching ASOs targeting the AURKA 5′ UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer 1.00
RNA-coupled CRISPR screens reveal ZNF207 as a regulator of LMNA aberrant splicing in progeria 1.00
Cell-surface RNA forms ternary complex with RNA-binding proteins and heparan sulfate to recruit immune receptors 0.06
UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression 0.05
HSP90 buffers deleterious genetic variations in BRCA1 1.00
Accumulation of succinate suppresses de novo purine synthesis through succinylation-mediated control of the mitochondrial folate cycle 1.00
Productive mRNA chromatin escape is promoted by PRMT5 activity 1.00
Targeted citrullination enables p53 binding to non-canonical sites 0.95
A Leishmania virulence factor harnesses an allosteric kinase switch to regulate its ubiquitin ligase activity 0.06
mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport 0.89
RAD51 is chromatin enriched and targetable in BRCA1-deficient cells 1.00
Endocytosis is essential for cysteine-deprivation-induced ferroptosis 0.90
HIF-independent oxygen sensing via KDM6A regulates ferroptosis 0.90
β-catenin functions as a molecular adapter for disordered cBAF interactions 0.83
Chromosomal tethering and mitotic transcription promote ecDNA nuclear inheritance 1.00
Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer 1.00
The immortality mechanism of TERT promoter mutant cancers is self-reinforcing and reversible 1.00
1 0.87
Overactive Neuronal eEF2K/eEF2 signaling is associated with cognitive impairment and apathy-like behavior 0.87
5 3.88
HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering 0.78
HER2 Antibody–Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody–Drug Conjugates 1.00
Photoacoustic Chemical Imaging of Tumor Microenvironment pH for Prediction of Chemotherapeutic Efficacy in Breast Cancer 1.00
Multivalent Metal–Nucleotide Nanoagonists Amplify Innate Immune Activation for Cancer Metalloimmunotherapy 0.10
Sodium Chloride Nanoparticles Potentiate Radiation Therapy by Disrupting Osmolarity Balance and Enhancing Antitumor Immunity 1.00
63 41.92
Ecotypes of triple-negative breast cancer in response to chemotherapy 1.00
Androgen loss accelerates brain tumour growth via HPA axis activation 0.93
Evolutionary characterization of lung cancer metastasis 0.01
A pro-carcinogenic bacterial toxin binds claudin-4 to cleave E-cadherin 0.86
Early fibrotic niches establish tumour-permissive microenvironments 0.25
Template-driven scaffolding of SCFFBXO42 regulates PP2A degradation 1.00
Epigenetic memory of colitis promotes tumour growth 1.00
Dominant clones leverage developmental epigenomic states to drive ependymoma 0.94
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma 0.48
Catabolism of extracellular glutathione supplies cysteine to support tumours 1.00
Thymic health and immunotherapy outcomes in patients with cancer 0.52
Multidimensional profiling of heterogeneity in supratentorial ependymomas 0.63
Ageing promotes metastasis via activation of the integrated stress response 0.10
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer 0.73
A glucocorticoid–FAS axis controls immune evasion during metastatic seeding 1.00
OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours 1.00
The integrated stress response promotes immune evasion through lipocalin 2 0.75
Ancient co-option of LTR retrotransposons as yeast centromeres 0.55
Ancestry and somatic profile indicate acral melanoma origin and prognosis 0.18
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance 0.13
Tumour–brain crosstalk restrains cancer immunity via a sensory–sympathetic axis 1.00
Critical role for a high-plasticity cell state in lung cancer 1.00
The ubiquitin ligase KLHL6 drives resistance to CD8 T cell dysfunction 0.32
Bidirectional CRISPR screens decode a GLIS3-dependent fibrotic cell circuit 1.00
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.57
Somatic evolution following cancer treatment in normal tissue 0.00
Whole-genome landscapes of 1,364 breast cancers 0.48
NSD2 targeting reverses plasticity and drug resistance in prostate cancer 0.88
Progressive coevolution of the yeast centromere and kinetochore 0.38
Polyclonal origins of human premalignant colorectal lesions 0.92
Genetic elements promote retention of extrachromosomal DNA in cancer cells 0.94
Targeting FSP1 triggers ferroptosis in lung cancer 0.75
Anti-progestin therapy targets hallmarks of breast cancer risk 0.02
Lymph node environment drives FSP1 targetability in metastasizing melanoma 0.60
Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome 1.00
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade 0.99
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers 0.12
Sex and smoking bias in the selection of somatic mutations in human bladder 0.41
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA 1.00
Reprogramming neuroblastoma by diet-enhanced polyamine depletion 0.59
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma 1.00
Structural basis for mTORC1 activation on the lysosomal membrane 0.48
Functional synapses between neurons and small cell lung cancer 0.04
Fluctuating DNA methylation tracks cancer evolution at clinical scale 0.10
Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis 1.00
Human gastroids to model regional patterning in early stomach development 0.10
Mechanical confinement governs phenotypic plasticity in melanoma 0.87
A missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia 0.01
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors 0.95
Axonal injury is a targetable driver of glioblastoma progression 0.10
Structural basis for the dynamic regulation of mTORC1 by amino acids 0.88
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy 0.84
Expanding the cytokine receptor alphabet reprograms T cells into diverse states 1.00
Respiratory viral infections awaken metastatic breast cancer cells in lungs 0.86
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity 0.96
Humoral determinants of checkpoint immunotherapy 1.00
Neutrophils drive vascular occlusion, tumour necrosis and metastasis 0.98
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.59
PPP2R1A mutations portend improved survival after cancer immunotherapy 1.00
Nerve-to-cancer transfer of mitochondria during cancer metastasis 1.00
Barcoded viral tracing identifies immunosuppressive astrocyte–glioma interactions 0.91
Spatiotemporal orchestration of mitosis by cyclin-dependent kinase 0.25
Metabolic adaptations direct cell fate during tissue regeneration 1.00
4 3.89
Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models 1.00
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma 1.00
Antibody–bottlebrush prodrug conjugates for targeted cancer therapy 1.00
Modifications of microbiome-derived cell-free RNA in plasma discriminates colorectal cancer samples 0.89
9 7.57
Cancer-associated fibroblasts regulate DNA repair in pancreatic cancer through NDRG1-mediated R-loop processing 0.83
Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine–ZBTB5–mTORC1 axis 0.13
An EGFR co-amplified lncRNA HELDR promotes glioblastoma malignancy through KAT7-driven gene programs 1.00
Nonsense-mediated mRNA decay safeguards telomeres in pluripotent stem cells 1.00
p53 increases phospholipid headgroup scavenging in senescence 1.00
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer 0.95
DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth 1.00
Enhancer activation from transposable elements in extrachromosomal DNA 1.00
A ROS-mediated oxidation-O-GlcNAcylation cascade governs ferroptosis 0.65
10 8.91
Genetically targeted mTORC1 inhibitor reveals transcriptional control by nuclear mTORC1 1.00
MEK interactions tune RAF kinase sensitivity to conformation-selective inhibition 1.00
Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs 1.00
IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers 1.00
Engineering synthetic agonists for targeted activation of Notch signaling 1.00
ELOVL6 activity attenuation induces mutant KRAS degradation 0.85
Highly specific intracellular ubiquitination of a small molecule 0.98
ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC 0.97
In situ proximity labeling of proteins associated with circRNA and RNA G-quadruplexes 0.17
A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1 0.95
349 223.93
Functional implications of the conformational landscape of a multidrug transporter revealed by Zebrafish Abcb4 structures 1.00
Potential for risk reduction of chronic health conditions through lifestyle in childhood cancer survivors 0.78
Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies 0.95
Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases 1.00
Fusion-positive rhabdomyosarcoma oncofusions share a common interactome 0.69
Resolving thyroid lineage cell trajectories merging into a dual endocrine gland in mammals 0.13
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial 1.00
ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer 0.84
RBM20 isoform regulation by independent transcription start sites adapts alternative splicing in development and disease 0.08
Near-infrared fluorescence imaging-guided surgery using cRGD-ZW800 to improve surgical resection margins in oral cancer: a phase I/II feasibility trial 0.05
Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ 0.97
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers 1.00
High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities 0.22
Dynamic breast MRI with Flexible Temporal Resolution Aided by Deep Learning 0.83
Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response 1.00
Systematic discovery of motif-based interactions of the auxiliary domains of USP family deubiquitinases 0.04
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial 1.00
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy 0.97
Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study 1.00
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial 0.06
Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer 0.97
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial 0.55
CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy 0.08
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial 1.00
Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies 1.00
Periodontitis induces skeletal muscle atrophy by increasing circulating levels of activin A. 0.11
NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer 0.81
A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy 1.00
Correction of the molecular phenotype of X-linked Dystonia-Parkinsonism reveals a non-canonical function of BRD4 0.20
Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models 1.00
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer 1.00
Activating p53Y220C with a mutant-specific small molecule 0.82
NAE1/UBA3-UBE2M are E1 and E2 enzymes for the URM1 modification 1.00
Boosting immunogenic tumour cell death via nanotherapeutic targeting of the Stanniocalcin 1 phagocytosis checkpoint for enhanced cancer immunotherapy 1.00
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer 0.01
Assessing the contribution of rare DNA states to cancer mutational signatures using sequence-specific conformational fingerprinting 1.00
Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22 0.75
Highly mutagenic copying of telomeric circles promotes ALT establishment 1.00
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients 0.05
Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations 0.13
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer 0.81
Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses 1.00
Pervasive non-triplet alternative splicing drives functional isoform diversity 1.00
Vitamin D binding protein induces skeletal muscle atrophy and contributes to cancer-associated muscle wasting independently of vitamin D status in preclinical models 0.07
Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination 0.04
CRISPR activation screens identify oncogenic lncRNAs that are susceptible to CDK4/6 inhibitor treatment 1.00
Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs  1.00
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study 0.98
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial 0.03
SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity 0.95
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response 0.92
In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicity 1.00
Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures 0.79
Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer 1.00
MYC-induced USP10 stabilizes SOX4 to promote thymocyte proliferation and leukemia onset in mice 0.08
TFEB degradation is regulated by an IKK/β-TrCP2 phosphorylation-ubiquitination cascade 1.00
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.25
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER HER2 locally-advanced or metastatic breast cancer 0.89
Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models 0.03
Epitranscriptomic RNA editing resolves Mus81 DNA repair tradeoffs in heat tolerance and meiosis 0.11
Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcoma 0.06
Neoantigen evolution and response to checkpoint inhibitor immunotherapy in colorectal cancer 1.00
FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment 1.00
Iminium-linked hyperporphyrin covalent organic framework mediates type I photodynamic therapy via a photoredox process 0.86
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial 1.00
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study 0.61
Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction 1.00
Vascular invasion-associated gene expression is detectable in pre-surgical biopsies of stage I lung adenocarcinoma 1.00
Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target 0.11
AP-1 mediates cellular adaptation and memory formation 1.00
Structural basis for prostaglandin and drug transport via SLCO2A1 0.18
IVNS1ABP mutation drives cellular senescence in newly identified progeroid neuropathy 0.13
Subgroup performance of a commercial digital breast tomosynthesis model for breast cancer detection 0.77
Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signaling 1.00
Engineering programmable CAR and antigen pairing via drug-gated light activation 0.87
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial 1.00
The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study 0.99
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors 0.07
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study 0.97
Multitrait GWAS and functional validation reveal genetic loci for gastric cancer 0.15
Targeting Prolyl 3-hydroxylase 1 inhibits pancreatic cancer progression and macrophage immunity 0.05
VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING 0.17
Megakaryocyte and platelet thrombospondin-1 regulates matrix remodeling by stabilizing basement membrane COL6A1 in lung injury 0.98
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer 0.71
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study 0.63
A large-scale genome-wide association meta-analysis for nevus count provides direct insights into the genetics of melanoma 0.10
Protection of telomeres 1b safeguards the Arabidopsis genome by regulating ROS homeostasis 0.97
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma 0.08
Tumor-induced orexigenic imbalance lowers protein appetite and drives early organ wasting symptoms 1.00
A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance 0.93
Cryo-EM structures of UBA6 reveal mechanisms of E1–E2 specificity and dual FAT10/ubiquitin thioester transfer 1.00
Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis 0.05
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial 1.00
Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma 1.00
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer 0.18
The nuclease EXO1 promotes genomic instability by degrading nascent DNA in BRCA-proficient cells 1.00
A gated hydrophobic funnel within BAX binds bioactive lipids to potentiate pro-apoptotic function 1.00
Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC 0.30
A spatially resolved human glioblastoma atlas reveals distinct cellular and molecular patterns of anatomical niches 0.12
Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy 0.89
Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4 0.67
Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma 1.00
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) 0.12
T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2+ solid and hematologic cancers 1.00
Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription 1.00
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial 0.27
FOXJ1 mediates taxane resistance through regulation of microtubule dynamics 1.00
Structural and molecular basis for allosteric regulation and catalytic coupling of human phosphoribosylformylglycinamidine synthase 1.00
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss 1.00
Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC 0.94
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial 1.00
Phytic acid (InsP6) activates HDAC3 epigenetic axis to maintain intestinal barrier function 0.79
A role for condensin-mediator interaction in mitotic chromosome organization 0.46
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies 1.00
Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis 1.00
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial 0.17
Inhibition of stress resilience and adult hippocampal neurogenesis by platelet-derived LPA16:0 in anxiety 0.10
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy 0.64
Early diagnosis of pancreatic ductal adenocarcinoma by signal-enhanced lateral flow immunoassay: SELFI 0.04
Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor 1.00
Indolent primary cutaneous B-cell lymphomas resemble persistent antigen reactions without signs of dedifferentiation 0.05
Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial 1.00
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C 1.00
Cancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15 1.00
Olutasidenib in recurrent/relapsed locally advanced or metastatic -mutated chondrosarcoma: phase 1b/2 trial 0.55
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial 1.00
Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice 1.00
CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting 0.02
Modulation of Nudt21 levels reveals dose-dependent roles of alternative polyadenylation in tissue regeneration 0.75
De novo variants in the splicing factor gene are associated with neurodevelopmental disorders 0.24
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction 0.98
Structures of nucleotide-bound human telomerase at several steps of its telomeric DNA repeat addition cycle 0.33
ZNF683 NK cells govern chemotherapy sensitivity in advanced HPSCC via reshaping immune microenvironment 0.04
Site-saturation functional screens identify PALB2 missense variants associated with increased breast cancer risk 0.11
Control of telomerase recruitment and end protection by independent shelterin components 1.00
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge 0.68
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) 0.06
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis 0.78
RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance 0.95
Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors 1.00
Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer 1.00
WRN structural flexibility showcased through fragment-based lead discovery of inhibitors 0.88
Oxidative stress and GPX2 control pancreatic vs. non-pancreatic cell fate in human endoderm 0.11
A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands 1.00
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers 1.00
Mechanistic insights into recruitment and regulation of the RNA helicase UPF1 in replication-dependent histone mRNA decay 0.13
Design of precision therapeutics for a CKD risk allele by targeting Shroom3-Rock interaction 0.95
Deep Mutational Scanning of FDX1 Identifies Key Structural Determinants of Lipoylation and Cuproptosis 1.00
Synovial sarcoma reprograms transcription by GBAF activation of polycomb targets and loss of CBAF enhancers 0.71
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors 1.00
Reconstructing the three-dimensional architecture of extrachromosomal DNA with ec3D 0.91
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer 1.00
Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome 0.06
The molecular cartography of malignant and benign sebaceous tumours 0.13
ER degradation for ER+/HER2– advanced or metastatic breast cancer: a phase 1 trial 1.00
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer 0.53
Loss of ALK4 promotes cancer progression through regulating TGF-β receptor N-glycosylation 1.00
Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy 1.00
Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma 0.80
Structural basis for genome-wide site-specific DNA recognition by Nuclear Factor IA 0.08
Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma 0.01
αPD-1-conjugated acid-cleavable nanodrugs overcomes cellular immunotherapy barriers in pancreatic tumors 0.06
Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma 0.03
Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy 0.05
APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling 1.00
Histone acetylation homeodynamics navigates cell survival and apoptosis 0.08
Early genetic evolution of driver mutations in uveal melanoma 0.97
USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer 0.61
Motorized chromosome models of mitotic chromosome folding 0.50
Lypd6b depletion promotes CD8+ T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer 0.07
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction 0.77
The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma 0.97
Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence 0.56
SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress 1.00
Ubiquitination by HRD1 is essential for TLR3 trafficking and its innate immune signaling 0.10
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors 1.00
Fragment-based discovery enables direct targeting of the melanoma oncogene MITF 0.21
Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral blood 0.06
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.03
Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma 0.95
Metabolic support protects mucosa from ferroptosis in radiation-induced mucositis 0.07
EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection 0.95
Therapeutic 6-thio-deoxyguanosine inhibits telomere elongation in cancer cells by inducing a non-productive stalled telomerase complex 1.00
INSM1 governs a neuronal progenitor state that drives glioblastoma in a human stem cell model 0.97
Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer 0.98
Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer 0.07
Hologenomic analysis of rectal mucus sampling for detection of adenomatous polyps and colorectal cancer 0.03
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial 1.00
The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells 0.04
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations 0.80
Programmable Argonaute-mediated single-nucleotide variant sequencing of cell-free DNA for multi-cancer early detection 0.97
Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies 0.15
DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance 0.92
The fibroblast epigenome underlies SS18::SSX-mediated transformation in synovial sarcoma 0.15
Multilayered regulation of TORC1 signaling by Ait1, Gcn2, and SEAC/GATOR during nitrogen limitation and starvation 1.00
Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1 0.07
Bipolar and schizophrenia risk gene encodes an autophagy receptor coupling the regulation of PKA kinase network homeostasis to synaptic transmission 1.00
The CTLH ubiquitin ligase substrates ZMYND19 and MKLN1 negatively regulate mTORC1 at the lysosomal membrane 1.00
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer 1.00
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial 1.00
Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis 0.02
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination 0.05
Enhancer regulator MLL4 controls skeletal muscle metabolic efficiency by limiting AMPK-mediated fuel catabolism 0.12
Subgroup of meningiomas involving FOS and FOSB gene fusions 0.99
Whole-body CD8 T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study 0.11
Single-cell multi-omics identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma 1.00
Cancer-associated snaR-A noncoding RNA interacts with core splicing machinery and disrupts processing of mRNA subpopulations 1.00
Bioorthogonal optimized virus immuno-nanomedicine (BOVIN) 0.25
Non-canonical roles of Keap1/Nrf2 in regulating quiescence and early activation in adult muscle stem cells 0.09
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence 1.00
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial 1.00
A ternary switch model governing ERα ligand binding domain conformation 0.38
Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors 1.00
Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer 0.05
Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia 0.95
SLC45A4 encodes a peroxisomal putrescine transporter that promotes GABA de novo synthesis 1.00
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling 1.00
Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment 0.26
Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma 0.17
Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency 0.05
RAF inhibitors activate the integrated stress response by direct activation of GCN2 0.21
Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation 0.05
KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2 1.00
The /EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs 0.96
A non-canonical lymphoblast in refractory childhood T-cell leukaemia 0.21
Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma 0.94
CryoEM and computational modeling structural insights into the pH regulator NBCn1 0.69
Pathogenic variants in cause an X-linked neurodevelopmental disorder modulated by NURF complex composition 0.35
Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma 0.88
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models 1.00
Oncogenic DEAD-box ATPase DDX41 establishes transcript ensembles via CLK3-dependent and -independent mechanisms 1.00
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy 0.05
Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies 0.59
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models 1.00
Real-world data and clinical experience from over 100,000 multi-cancer early detection tests 1.00
Single rate-limiting event of carcinogenesis 0.25
BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability 0.71
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling 0.85
EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma 0.02
Genome-wide association study of childhood B-cell acute lymphoblastic leukemia reveals novel African ancestry-specific susceptibility loci 0.98
Mitochondrial one-carbon metabolism is required for TGF-β-induced glycine synthesis and fibrotic responses 1.00
Leveraging platinum-protein interactions to overcome chemoresistance 1.00
Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors 0.95
WEE1 inhibitors synergise with mRNA translation defects via activation of the kinase GCN2 0.05
Metabolic profiling reveals channeled de novo pyrimidine and purine biosynthesis fueled by mitochondrially generated aspartic acid in cancer cells 1.00
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer 0.29
The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia 0.31
The Hippo terminal effector YAP boosts enterovirus replication in type 1 diabetes 0.09
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer 0.58
Dual membrane receptor degradation via folate receptor targeting chimera 1.00
Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry 0.13
CXCR4 mediated recognition of HIV envelope spike and inhibition by CXCL12 0.57
An active allosteric mechanism in ASAP1-mediated Arf1 GTP hydrolysis redefines PH domain function 1.00
Structural insights into chemoresistance mutants of BCL-2 and their targeting by stapled BAD BH3 helices 1.00
Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice 1.00
Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors 0.89
In vivo CRISPR screening in head and neck cancer reveals as an immunotherapy target 0.99
Cytoplasmic TRIM24 promotes colorectal cancer cell proliferation by activating Wnt/β-catenin signaling 0.08
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial 0.90
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity 0.88
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity 0.91
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer 1.00
Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC 0.08
Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series 0.10
Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation 1.00
Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma 1.00
PYM1 limits non-canonical Exon Junction Complex occupancy in a gene architecture dependent manner to tune mRNA expression 1.00
A -natural antisense RNA regulates alternative polyadenylation of under Pi starvation in tomato 0.13
Hypoxic stress incites HIF1α-driven ribosome biogenesis that can be exploited by targeting RNA Polymerase I 1.00
Hepatitis C virus NS3 helicase contributes to (−) strand RNA synthesis 0.20
Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy 0.01
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 0.13
Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer 0.01
Whole exome sequencing identifies as a susceptibility gene for estrogen-receptor-negative breast cancer in Hispanic/Latina women 0.95
Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis 0.92
modulates p53, the cell cycle, and genotoxicity to maintain its intracellular niche 1.00
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma 0.82
CENcyclopedia: dynamic landscape of kinetochore architecture throughout the cell cycle 1.00
Computational ranking identifies Plexin-B2 in circulating tumor cell clustering with monocytes in breast cancer metastasis 1.00
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers 0.94
Respiration defects limit serine synthesis required for lung cancer growth and survival 1.00
Multivalent interactions with CCR4–NOT and PABPC1 determine mRNA repression efficiency by tristetraprolin 1.00
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy 1.00
COUP-TFII-mediated reprogramming of the vascular endothelium counteracts tumor immune evasion 1.00
Nucleophilic addition promoted ring rearrangement-aromatization in aza-/thio-sesquiterpenoid biosynthesis 0.07
Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients 0.95
Structure and function of the human apoptotic scramblase Xkr4 1.00
DDX41 resolves G-quadruplexes to maintain erythroid genome integrity and prevent cGAS-mediated cell death 1.00
Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function 0.05
Neural function of Netrin-1 in precancerous lesions of the pancreas 0.11
Pre-mRNA processing factors differentially impact coordination between co-transcriptional cleavage and transcription termination 0.12
Structure of CFTR bound to ()-BPO-27 unveils a pore-blockage mechanism 1.00
Dynamic and structural insights into allosteric regulation on MKP5 a dual-specificity phosphatase 1.00
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas 0.70
De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer 0.85
U-rich elements drive pervasive cryptic splicing in 3’ UTR massively parallel reporter assays 1.00
Large-scale RNA-Seq mining reveals ciclopirox olamine induces TDP-43 cryptic exons 0.87
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study 0.47
Specific oncogene activation of the cell of origin in mucosal melanoma 1.00
ST2/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche 1.00
Allosteric activation of the SPRTN protease by ubiquitin maintains genome stability 0.11
Determination of trunk neural crest cell fate and susceptibility to splicing perturbation by the DLC1-SF3B1-PHF5A splicing complex 0.08
E2F activity determines mitosis versus whole-genome duplication in G2-arrested cells 1.00
The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cell states 0.03
Nanomechanical binding mechanism of ligands drives agonistic activity 0.08
The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy 1.00
Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC 1.00
Comprehensive ovarian cancer variant analysis uncouples homologous recombination and replicative functions 1.00
Marked heterogeneity in malaria infection rate in a Malian longitudinal cohort 0.90
The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations 0.01
Notch activity is modulated by the aGPCR Latrophilin binding the DSL ligand in C. elegans 0.08
TRF1 relies on fork reversal to prevent fragility at human telomeres 0.22
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B 0.67
Inferring chromosome segregation error stage and crossover in trisomic disorders with application to Down syndrome 0.95
Synthetic carbon-based lanthanide upconversion nanoparticles for enhanced photothermal therapy 0.17
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms 0.10
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma 1.00
Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors 0.03
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer 0.87
Decoding polyubiquitin regulation of K7. 1 (KCNQ1) surface expression with engineered linkage-selective deubiquitinases 1.00
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial 0.05
Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma 1.00
Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer 1.00
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial 0.02
Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial 1.00
Deficits in mitochondrial dynamics and iron balance result in templated insertions 1.00
Deep mutational scanning of the multi-domain phosphatase SHP2 reveals mechanisms of regulation and pathogenicity 1.00
Adipocyte-specific Zeb1 downregulation remodels the tumor-associated adipose microenvironment to facilitate female breast cancer progression 0.04
Single-cell analysis reveals a longitudinal trajectory of meningioma evolution and heterogeneity 0.02
Structural mechanism of DDX39B regulation by human TREX-2 and a related complex in mRNP remodeling 1.00
Aging measures and cancer in the Health and Retirement Study (HRS) 1.00
Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny 1.00
Interdependence of Pasha and Drosha for localization and function of the Microprocessor in C. elegans 0.83
A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression 0.09
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial 0.03
CryoEM structure of the SLFN14 endoribonuclease reveals insight into RNA binding and cleavage 1.00
Single-cell signaling network profiling during redox stress reveals dynamic redox regulation in immune cells 0.03
An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy 1.00
Uncovering minimal pathways in melanoma initiation 1.00
Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance 0.03
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression 1.00
A macrophage-predominant immunosuppressive microenvironment and therapeutic vulnerabilities in advanced salivary gland cancer 0.04
Molecular patterns and mechanisms of tumorigenesis in HPV-associated and HPV-independent sinonasal squamous cell carcinoma 1.00
SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers 0.97
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence 0.90
Control of epithelial tissue organization by mRNA localization 1.00
The TRIP12 E3 ligase induces SWI/SNF component BRG1-β-catenin interaction to promote Wnt signaling 0.97
Inflammatory diseases and risk of lung cancer among individuals who have never smoked 1.00
High mobility group A1 (HMGA1) promotes esophageal squamous cell carcinoma progression by inhibiting STING-mediated anti-tumor immunity 0.12
34 21.24
Age distinguishes selection from causation in cancer genomes 0.80
High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia 0.77
Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study 0.13
Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes 0.26
Systematic analysis of snRNA genes reveals frequent variants in dominant and recessive developmental and epileptic encephalopathies 0.08
Biallelic variants in cause the most prevalent known recessive neurodevelopmental disorder 0.41
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.48
CDK4/6 inhibition mitigates chemotherapy-induced expansion of -mutant clonal hematopoiesis 0.97
Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types 0.07
Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases 0.67
Childhood brain tumors instruct cranial hematopoiesis and immunotolerance 0.13
Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry 0.88
Genomic evolution of pancreatic cancer at single-cell resolution 0.95
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.10
A breakage–replication/fusion process explains complex rearrangements and segmental DNA amplification 1.00
Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma 0.06
Passenger mutations link cellular origin and transcriptional identity in human lung adenocarcinomas 1.00
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer 0.99
Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer 0.47
Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma 1.00
Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas 0.79
Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer 0.69
Rapid epigenomic classification of acute leukemia 0.91
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis 0.05
Mutational landscape of triple-negative breast cancer in African American women 1.00
ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L 1.00
Tamoxifen induces PI3K activation in uterine cancer 0.66
Temporal genomic dynamics shape clinical trajectory in multiple myeloma 0.66
Tracing the evolution of single-cell 3D genomes in Kras-driven cancers 1.00
NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling 1.00
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation 0.91
The long-term effects of chemotherapy on normal blood cells 0.09
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A 0.26
Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination 1.00
9 5.72
Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer 0.94
Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8+ T cells in lymph nodes 0.03
BACH2 regulates T cell lineage state to enhance CAR T cell function 1.00
BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells 1.00
PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming 0.88
Pseudokinase STK40 limits T cell exhaustion through COP1-dependent degradation of AP1-family transcription factors 1.00
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma 0.06
The transcription complex p52–ETS1 is essential for germinal center formation 0.06
Succinate drives gut inflammation by promoting FOXP3 degradation through a molecular switch 0.74
4 3.05
Restoring the tumour mechanophenotype of vocal fold cancer reverts its malignant properties 0.05
IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer 1.00
Tumour priming by ultrasound mechanogenetics for CAR T therapy 1.00
Local photocrosslinking of native tissue matrix regulates lung epithelial cell mechanosensing and function 1.00
47 30.07
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial 1.00
CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial 0.96
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial 0.98
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial 1.00
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial 0.79
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial 1.00
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial 0.44
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial 0.99
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.41
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 0.37
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial 1.00
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial 0.18
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.46
Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade 0.97
Abemaciclib in meningiomas with somatic or CDK pathway alterations: the phase 2 Alliance A071401 trial 1.00
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial 0.69
CD4 T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy 1.00
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma 0.11
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial 0.90
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma 0.33
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial 1.00
Targeting of HIF2-driven cachexia in kidney cancer 1.00
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial 1.00
Microbial signals in primary and metastatic brain tumors 1.00
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial 0.12
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial 0.83
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.50
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial 0.82
Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life 0.60
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study 0.92
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.24
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial 0.57
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.12
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses 0.95
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial 0.11
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial 1.00
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial 0.02
Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results 0.10
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial 1.00
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results 1.00
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.50
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial 0.38
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.23
AI-based large-scale screening of gastric cancer from noncontrast CT imaging 0.02
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial 0.33
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer 0.18
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial 0.97
2 0.21
An encyclopedic regulatory and functional atlas of RNA interactomes 0.13
Unraveling lncRNA diversity at a single cell resolution and in a spatial context across different cancer types 0.08
6 4.96
Enhancing antitumour nanovaccine efficacy via integrated cholesterol modulation in situ 0.08
Prodrug-tethered lipid nanoparticles for synergistic messenger RNA cancer immunotherapy 0.98
AND logic nanoparticle for precision immunotherapy of metastatic cancers 1.00
An ultrasmall core–shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments 1.00
Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature 1.00
Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles 0.90
4 3.39
TDP-43 loss induces cryptic polyadenylation in ALS/FTD 0.68
TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes 0.96
Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape 0.75
Aberrant splicing exonizes C9orf72 repeat expansion in ALS/FTD 1.00
11 8.99
Vitamin B2 metabolism promotes FSP1 stability to prevent ferroptosis 0.78
A proteome-wide dependency map of protein interaction motifs 0.04
Heterochromatin boundaries maintain centromere position, size and number 0.17
DICER1 hotspot mutation induces 3p microRNA gain of function via Argonaute strand switch 1.00
Mechanistic basis for protein conjugation in a diverged bacterial ubiquitination pathway 1.00
RNase MRP subunit composition and role in 40S ribosome biogenesis 1.00
Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification 1.00
Cytoplasmic PXR regulates glucose metabolism by binding mRNAs and modulating their stability 1.00
Structural basis for mTORC1 regulation by the CASTOR1–GATOR2 complex 1.00
The PURB–HOTAIR complex regulates p53-dependent promoter-specific transcriptional activation 1.00
Comprehensive analysis of Saccharomyces cerevisiae intron structures in vivo 1.00
8 6.77
ATF2 phosphorylation is a core transcriptional driver of neuron apoptosis 1.00
Secreted GPNMB enhances uptake of fibrillar alpha-synuclein in a non-cell-autonomous process that can be blocked by anti-GPNMB antibodies 1.00
A local sympathetic-immune axis inhibits melanoma growth in mice by dictating adrenergic control 1.00
DCPS modulates TDP-43-linked neurodegeneration through P-body-mediated RNA decay 1.00
C9orf72 hexanucleotide repeat RNA drives transcriptional dysregulation through genome-wide DNA:RNA hybrid G-quadruplexes 1.00
Reactive oligodendrocytes promote glioblastoma progression through CCL5/CCR5-mediated glioma stem cell maintenance 0.11
Polyserine-mediated targeting of FAF2/UBXD8 ameliorates tau aggregation 0.67
Aberrant coupling of glutamate and tyrosine kinase receptors enables neuronal control of brain-tumor growth 1.00
3 1.93
Discovery of seco-(9β-H)-Pimarane Diterpenoids from Icacina oliviformis with Synergistic Anti-Colorectal Cancer Activity 0.18
Asymmetric Total Synthesis of Daucane-Type Sesquiterpenoids (+)-Ferutinin and (+)-Kuhistanicaol G 0.75
Total Synthesis of Dahurelmusin A and iepi/i-Dahurelmusin A: Effect of a Single Stereocenter Change on Biological Activity 1.00
4 4.00
TDP-43-mediated alternative polyadenylation is associated with a reduction in VPS35 and VPS29 expression in frontotemporal dementia 1.00
The deubiquitinating enzyme Cezanne stabilizes BRCA1 by counteracting APC/C and Ube2S-dependent Lys11-linked ubiquitination 1.00
The cell cycle regulator PLK1 promotes murine melanoma progression by regulating the transcription factor BACH1 1.00
A hormone-dependent tRNA half promotes cell cycle progression via destabilization of p21 mRNA 1.00
14 11.93
Lactate and histone H3K18 lactylation are associated with metabolic control of gene expression in the retina 0.96
Metabolic and behavioral effects of neurofibromin result from differential recruitment of MAPK and mTOR signaling 1.00
Protein-interaction network analysis reveals the role of Prp19 splicing factor in transcription of both intron-containing and intron-lacking genes 1.00
The conserved SEN1 DNA/RNA helicase has multiple functions during yeast meiosis 1.00
Fibroblast mechanoperception instructs pulmonary developmental and pattern specification gene expression programs 1.00
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma 0.17
Spatial colocalization and molecular crosstalk of myofibroblastic CAFs and tumor cells shape lymph node metastasis in oral squamous cell carcinoma 0.21
Clusters of deep intronic RbFox motifs embedded in large assembly of splicing regulators sequences regulate alternative splicing 0.75
Single-cell analysis of gene regulatory networks in the mammary glands of P4HA1-knockout mice. 1.00
Protein sequence editing defines distinct and overlapping functions of SKN-1A/Nrf1 and SKN-1C/Nrf2 1.00
Activation of Pvt1b isoform contributes to local Pvt1 abundance to repress Myc during stress. 1.00
Role of the SAF-A/HNRNPU SAP domain in X chromosome inactivation, nuclear dynamics, transcription, splicing, and cell proliferation 1.00
Cell cycle dependent methylation of Dam1 contributes to kinetochore integrity and faithful chromosome segregation. 0.83
Visualizing androgen signaling and assessing its interaction with canonical Wnt signaling pathways in prostate development, morphogenesis, and regeneration 1.00
4 3.14
Subsequent primary cancer incidence among cancer survivors in the United States, 1975–2019: An age–period–cohort analysis 1.00
Association of hydralazine use with risk of hematologic neoplasms in patients with hypertension: A nationwide population-based cohort study in Taiwan 0.14
Prognostic significance of CD8+ T cell Spatial Biomarkers in ER+ and ER− breast cancer: A retrospective cohort study 1.00
Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study 1.00
139 109.84
NF1 and SPRED1/2 cooperate through RAS-MAPK-independent functions 1.00
Oxidative stress and serum deprivation influence the evolution of newly formed tetraploid cells during tumorigenesis 1.00
NRF2 activation by myeloid cell–derived oxidative stress induces SNAI-driven features of EMT in breast cancer 0.13
A BCG hydrogel enables localized NOD2/STING activation to overcome resistance to immune checkpoint blockade 0.10
Transcription start site heterogeneity controls MDA5 sensing of unspliced HIV-1 RNAs 1.00
A broad-spectrum inhibitor of copper-exporting P1B-type ATPases 0.89
NEK2 drives pathogenesis, drug resistance, and LMP1 expression in EBV-positive non-Hodgkin lymphoma 1.00
Deep-learning endomicroscope with large field-of-view and depth-of-field for real-time in vivo imaging of epithelial cancer hallmarks 1.00
MiR-155-driven loss of ICOSL and SOCS1 in EBV+ gastric cancers renders abundant cytotoxic T cells ineffective, enabling immune evasion 0.60
Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma 0.23
An Octopus probe for high-performance >1,300 nm NIR-II fluorescence molecular imaging of cancer 0.03
The antimetastatic effects of calorie restriction are negated by voluntary exercise in an aggressive breast cancer mouse model 0.82
Restoring the 14-3-3/CRAF regulatory interaction in Noonan syndrome using molecular glues 0.63
Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy 0.38
A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation 1.00
Amoeboid–mesenchymal transition and the proteolytic control of cancer invasion plasticity 1.00
Many paths to destruction: Family-specific turnover and stress responses for tRNA introns 1.00
Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion 1.00
Structure-guided design of 7-azaindole DNMT1 inhibitors active against hypomethylating agent–resistant acute myeloid leukemia 0.12
Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer 0.11
STAG2 loss amplifies EWS-FLI1-driven microsatellite enhancer activity promoting Ewing sarcoma aggressiveness 1.00
Structure basis for C-C chemokine receptor 4 modulation by orthosteric and allosteric antagonists 1.00
A C-degron regulates Chk1 kinase by allowing stability of inactive Chk1 and by making it short- lived upon activation 1.00
Aging alters DNA structure–induced genetic instability in mice 1.00
Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test 0.96
Oocyte-inspired universal whole-cell vaccines against tumor heterogeneity 0.13
How do RNA molecules distinguish self from non-self? 1.00
Functional role of small extrachromosomal circular DNA in colorectal cancer 0.27
Regulation of STK38 by autophagy governs YAP1 activity during paligenosis 1.00
Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis, and diminishes cell motility signaling 1.00
Targeting the ANGPTL4/NRP1/ABL1/RAD51 axis reverses cisplatin resistance by impairing DNA damage repair in head and neck cancer 1.00
A modular platform for Sterically Masked Activated Cytokines (SMACks) 1.00
Unveiling the developmental and tumor-suppressive roles of the p53 variant p53psi 0.05
Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade 1.00
Synthetic SIGLEC9-based chimeric switch receptor augments the efficacy of CAR macrophages against glioblastoma 0.03
Mutually exclusive alternative pre-mRNA splicing promotes adaptive metabolic stress signaling by JNK 1.00
Microglial fructose metabolism is essential for glioblastoma growth 0.97
BRCA1-A and LIG4 complexes mediate ecDNA biogenesis and cancer drug resistance 1.00
Viral mimicry may help explain immunogenic cell death 1.00
Ubiquitin-specific peptidase-19 links TDP-43 aggregation to ER stress 0.91
HPV16 E6 oncoprotein promotes microhomology-mediated viral integration by increasing PolΘ protein expression 0.92
MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic cancer 1.00
Grin2b 3’UTR is necessary for synaptic plasticity and spatial learning 0.13
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer 1.00
ARP2/3 complex mediates the neuropathology of PTEN-deficient human neural cells downstream of mTORC1 and mTORC2 hyperactivation 0.06
A systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas 1.00
Metabolic stress conditions dictate MAPKAPK2-dependent efficiency of MEK1/2 inhibition in colorectal carcinoma 0.62
Variable thresholds for phosphorylation targets of the ERK signaling pathway 1.00
Evaluation of targeted and immune combination therapies in a rat model of hormone receptor–positive breast cancer 1.00
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers 1.00
PTP1B inhibition promotes microglial phagocytosis in Alzheimer’s disease models by enhancing SYK signaling 1.00
The kinetochore corona orchestrates chromosome congression through transient microtubule interactions 1.00
Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer 1.00
Integrated mutational landscape analysis of endometrial stromal sarcoma 0.32
Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug 0.77
Phosphatase SHP2 pathogenic mutations enhance activity by altering conformational sampling 1.00
Nonsense-mediated decay controls a negative feedback loop in innate immune sensing 1.00
Elucidating cooperative genetic events in DCIS progression in mutant p53–driven breast cancer 1.00
Mechanical compression induces neuronal apoptosis, reduces synaptic activity, and promotes glial neuroinflammation in mice and humans 1.00
Differential roles of type I topoisomerases in regulating HPV pathogenesis 1.00
Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2′-deoxyuridine (EdU) 1.00
Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition 0.50
Molecular mechanism of substrate transport by human peroxisomal ABCD3 1.00
Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery 1.00
Occludin acts as a dynein adaptor regulating permeability and collateral angiogenesis 0.96
Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy 1.00
Potentiation of ryanodine receptor–mediated calcium release by MAPK is responsible for epidermal transformation and carcinogenesis 0.50
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer 0.13
LHPP expression in triple-negative breast cancer promotes tumor growth and metastasis by modulating the tumor microenvironment 1.00
Guiding esophagectomy with intraoperative NIR-II fluorescence video imaging and rapid computation 0.03
Deciphering precursor cell dynamics in esophageal preneoplasia via genetic barcoding and single-cell transcriptomics 1.00
Oxidative pentose phosphate pathway is required for T cell activation and antitumor immunity 1.00
Immunogenic cell death unlocks the potential for combined radiation and immunotherapy 0.80
Engineered calcium-regulated affinity protein for efficient internalization and lysosomal toxin delivery 0.20
The lysosomal carrier SLC29A3 supports antibacterial signaling, and promotes autophagy by activating TRPML1 in murine dendritic cells 1.00
Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell–engineered mesothelin-redirected CAR-NKT cells 1.00
Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance 1.00
EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors 1.00
Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target 0.90
Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors 0.50
Forward genetic screening in engineered colorectal cancer organoids identifies regulators of metastasis 1.00
Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle 0.94
Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers 1.00
Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses 1.00
Genetic regulation of the estrogen receptor and inherited predisposition to breast cancer 1.00
Adipose cullin 3 mediates the antiobesity effect of pan neddylation inhibitors 1.00
Mutant p53 regulates cancer cell invasion in complex three-dimensional environments through mevalonate pathway–dependent Rho/ROCK signaling 0.92
Single-cell sequencing uncovers sensory neuron–mediated CGRP signaling as a driver of sarcoma progression 1.00
Small-molecule allosteric activator of ubiquitin-specific protease 7 (USP7) 1.00
Distinct and convergent effects of SF3B1 mutations in human breast cancer 1.00
Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas 1.00
Engineering antibody–drug conjugates targeting an adhesion GPCR, CD97 1.00
Biliverdin reductase A is a major determinant of protective NRF2 signaling 0.95
CAR-SPLASH identifies nascent pre-mRNA structures implicated in kinetic coupling and alternative splicing 0.67
A diverse family of bacterial deubiquitinases is defined by the Coxiella burnetii effector EmcB 1.00
A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy 0.79
Genetic dissection of nonconventional introns reveals codominant noncanonical splicing code in Euglena 0.02
Functional spectrum of USP7 pathogenic variants in Hao–Fountain syndrome: Insights into the enzyme’s activity, stability, and allosteric modulation 0.82
Ebola virus VP35 NNLNS motif modulates viral RNA synthesis and MIB2-mediated signaling 1.00
Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer 0.91
Kupffer cells are essential for platelet-mediated thrombopoietin generation in the liver 0.19
An in vitro BRAF activation assay elucidates molecular mechanisms driving disassembly of the autoinhibited BRAF state 1.00
Restoring mitochondrial quantity and quality to reverse the Warburg effect and drive neuroblastoma differentiation 1.00
Cellular cartography reveals mouse prostate organization and determinants of castration resistance 0.97
G-quadruplexes as a source of vulnerability in BRCA2-deficient granule cell progenitors and medulloblastoma 0.93
Programmable immunoprobiotics orchestrate antitumor immune response with Pin1 inhibition for pancreatic cancer treatment 1.00
GATA3 promotes ferroptosis resistance by repressing integrin β1 signaling 1.00
Reduction of TRAF3 by heterozygosity or aging impacts B cell function 1.00
The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasis 0.98
Transcription termination promotes splicing efficiency and fidelity in a compact genome 1.00
The activity and expression of adenylosuccinate lyase were reduced during modern human evolution, affecting brain and behavior 0.23
Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib 1.00
Ras-mediated dynamic and biphasic regulation of cell migration 1.00
Leveraging chromatin packing domains to target chemoevasion in vivo 1.00
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer 1.00
T lymphocyte–specific deletion of SHP1 and SHP2 promotes activation-induced cell death of CD4+ T cells and impairs antitumor response 1.00
Monensin suppresses EMT-driven cancer cell motility by inducing Golgi pH–dependent exocytosis of GOLIM4 1.00
p63 and ZNF148 cooperate to regulate head and neck squamous cell carcinoma 0.02
CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors 1.00
TEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway 1.00
A degradable form of polyoma small T antigen reveals the high specificity of TAZ in regulating gene expression 1.00
Akt isoform specificity drives intrinsic immune regulation during HSV-1 infection 1.00
Signal peptide–independent secretion of keratin-19 by pancreatic cancer cells 1.00
A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system 1.00
The role of estrogen receptor β in maintaining basal cells and modulating the immune environment in the prostate 0.58
Tumor-promoting UBR4 coordinates impaired mitophagy–associated senescence and lung adenocarcinoma pathogenesis 0.06
The oncogene SLC35F2 is a high-specificity transporter for the micronutrients queuine and queuosine 0.56
Single Antisense Oligonucleotides Correct Diverse Splicing Mutations in Hotspot Exons 0.89
Structural insights into the activation and inhibition of the ADAM17–iRhom2 complex 1.00
Local and distal changes in dynamics are caused by an L205R Cushing’s syndrome mutant in PRKACA 0.94
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma 0.87
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging 1.00
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activity 0.29
Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer 0.17
Dual-laser “808 and 1,064 nm” strategy that circumvents the Achilles’ heel of photothermal therapy 0.10
The highly conserved intron of tyrosine tRNA is critical for m1A58 modification and controls the integrated stress response 1.00
Epithelial Regnase-1 inhibits colorectal tumor growth by regulating IL-17 signaling via degradation of NFKBIZ mRNA 0.07
BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function 0.93
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response 0.38
20 14.02
Prediction of Lobar Emphysema Progression with a CT-Based Foundational Model 1.00
Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma. 1.00
Abbreviated MRI for the Evaluation of Treatment Response in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer. 1.00
Characterization of Clinically Significant Prostate Cancer in the Peripheral Zone Using Rapid B1-Insensitive MR Fingerprinting. 1.00
Optimizing Colorectal Liver Metastasis Ablation through Metabolic Imaging, Margin Assessment, and Biopsy (The OPTABLATE Prospective Trial). 0.96
Black-White Racial Differences in Background Parenchymal Enhancement at Breast MRI. 1.00
Prevalence, Co-occurrence, and Prognostic Implications of S Modifiers in the Korean National Lung Cancer Screening Program. 0.09
CT-based Radiologic Ternary Classification Model in Predicting Pathologic Invasiveness of Pulmonary Nonsolid Nodules. 0.30
Identification of Risk Factors for Interval Breast Cancer in a Population-based Screening Program. 0.08
Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in Situ. 0.35
MRI-based Habitat Analysis for the Prediction of Progression-Free Survival in Primary Spinal Tumors. 0.15
Feasibility of Auditing Preoperative Breast MRI for Extent-of-Disease Evaluation Using the BI-RADS v2025 Manual. 1.00
Molecular Breast Imaging and Digital Breast Tomosynthesis for Dense Breast Screening: The Density MATTERS Trial. 1.00
Clinical and Imaging Factors Impacting Positive Predictive Value of Prostate MRI. 1.00
External Testing of a Deep Learning Model for Lung Cancer Risk from Low-Dose Chest CT. 0.13
AI to Reduce the Interval Cancer Rate of Screening Digital Breast Tomosynthesis. 1.00
Cancer Detection in Breast MRI Screening via Explainable AI Anomaly Detection. 0.80
Screening for Breast Cancer with Contrast-enhanced Mammography as an Alternative to MRI: SCEMAM Trial Results. 1.00
Preoperative Diagnosis of Ipsilateral and Contralateral Breast Cancer: Role of Diffusion-weighted MRI. 0.17
Adaptive Breast MRI Scanning Using AI. 1.00
26 20.93
Intermetallic nanoassemblies potentiate systemic STING activation 1.00
Lymphoid tissue chemokines limit priming duration to preserve CD8+ T cell functionality 0.04
Stem cell control in the lung by an autocrine injury-activated Igf complex 1.00
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma 1.00
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer 1.00
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors 1.00
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics 1.00
Mechanisms linking cytoplasmic decay of translation-defective mRNA to transcriptional adaptation 0.94
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation 0.02
Chromothripsis and ecDNA initiated by N4BP2 nuclease fragmentation of cytoplasm-exposed chromosomes 0.89
Structural basis for the recruitment and selective phosphorylation of Akt by mTORC2 0.97
The synaptic ectokinase VLK triggers the EphB2–NMDAR interaction to drive injury-induced pain 1.00
NUDT5 regulates purine metabolism and thiopurine sensitivity by interacting with PPAT 1.00
Human RPA is an essential telomerase processivity factor for maintaining telomeres 1.00
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2 0.86
T cell cholesterol transport links intestinal immune responses to dietary lipid absorption 1.00
Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing 0.06
Structural basis for LZTR1 recognition of RAS GTPases for degradation 1.00
A hypoxia-responsive tRNA-derived small RNA confers renal protection through RNA autophagy 0.97
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA 0.05
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction 1.00
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors 1.00
Macrophage-derived oncostatin M repairs the lung epithelial barrier during inflammatory damage 1.00
Cryo-EM structure of human telomerase dimer reveals H/ACA RNP-mediated dimerization 0.17
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity 0.96
In vivo CAR T cell generation to treat cancer and autoimmune disease 1.00
94 71.47
SRSF3 determines Treg cell fate in antitumor immunity and autoimmunity 0.33
Single-nucleotide variant profiling in liquid biopsy with RECO-Cas 1.00
Multiplexed single-cell transcriptomics reveals diverse phenotypic outcomes for pathogenic SHP2 variants 1.00
Generalizability of an AI-based mammogram risk score (MRS) for breast cancer among diverse populations of women 1.00
P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML 0.78
A chromatin-associated pool of Aurora A controls kinetochore-microtubule attachments to ensure chromosome biorientation 1.00
Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity 1.00
TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia 0.18
Stress-induced CXCL13 regulates pancreatic exocrine homeostasis, age-related chronic inflammation, and cancer progression 0.06
Spliceosomal mutation drives melanoma tumorigenesis via lineage-specific RAS activation 0.10
PARP4 ADP-ribosylates PIDD1 to complete a phospho/SUMO/PAR-ylation cascade that orchestrates PIDDosome assembly 0.67
IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumors 0.91
MYC-bound enhancer RNAs in cis regulate gene transcription and tumorigenesis 1.00
Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity 0.82
Molecular basis of CXC chemokine receptor 3 ligand multispecificity 1.00
Histone decrotonylation plays a distinct role in HIV latency 1.00
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC 1.00
Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies 0.97
A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer 1.00
Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma 0.07
A synergistic interaction between PRMT5 and LSD1 inhibitors in AML 0.31
Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib 1.00
KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival 0.21
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis 0.22
Biodegradable targeted polymeric mRNA nanoparticles enable in vivo CD19 CAR T cell generation and lead to B cell depletion 1.00
IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells 1.00
Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcoma 0.78
Evidence that extra copies of chromosome 1q play a role in the early phases of pancreatic neoplasia 1.00
<atl>Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and iBAP1/i loss</atl> 0.93
Circular RNA circHomer1 mediates hippocampal functions via ribonucleoprotein granule transport and dendritic targeting of synaptic RNAs 0.19
Accessory microRNA byproducts expand RNA interference via microprocessor-mediated cleavage activation 0.83
Pyruvate kinase muscle 2 (PKM2) promotes CD4 T cell survival by regulating pyruvate oxidation during homeostasis and expansion 0.94
Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis 1.00
Selective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunity 1.00
Optimally engineered HLA/peptide-specific CAR-T cells outperform TCR-T cells to eradicate solid tumors 1.00
Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma 1.00
Impaired nitrogenous waste clearance promotes hepatocellular carcinoma 0.91
Synergistic intragenic epigenetic deregulation by IDH2 and SRSF2 mutations causes mis-splicing of key transcriptional regulators 0.89
FSP1 and histone deacetylases suppress cancer persister cell ferroptosis 1.00
Dual-receptor targeting of type I dendritic cells with DNA-scaffolded nanoparticles enhances STING-licensed antitumor immunity 1.00
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer 0.30
Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment 0.43
EGFR activation requires cholesterol interaction at the inner leaflet of the plasma membrane 0.14
Molecular effects of indoor tanning 0.98
Steric disruption of EGFR oligomerization overcomes therapy resistance in non–small cell lung cancer 0.50
Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation 0.28
Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models 1.00
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma 1.00
MeCP2 interacts with the super elongation complex to regulate transcription 1.00
Targeting cancer-associated fibroblasts for real-time intraoperative tumor identification with a spray-on fluorescent probe 0.67
Platelets induce endothelial cell mitochondrial dysfunction in myocardial infarction 1.00
Substrate recognition by human separase 0.50
Peptide-MHC–targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells 0.91
Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes 1.00
Tumor-derived RAC1A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor 1.00
Transcription factor activator protein 4 (AP4)–mediated intrinsic control of axon regeneration 0.17
Enhanced FOS expression improves tumor clearance and resists exhaustion in NR4A3-deficient CAR T cells under chronic antigen exposure 0.06
Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer 1.00
Resistance to radiation enhances metastasis by altering RNA metabolism 1.00
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup 0.94
Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia 0.76
Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases 1.00
Lysosomal LRRC8 complex impacts lysosomal pH, morphology, and systemic glucose metabolism 1.00
Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy 1.00
PTPN22-CD45 dual phosphatase retrograde feedback enhances TCR signaling and autoimmunity 0.90
Computational design of potent and selective binders of BAK and BAX 0.32
Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma 0.09
Deltex and RING-UIM E3 ligases cooperate to create a ubiquitin-ADP-ribose hybrid mark on tankyrase, promoting its stabilization 1.00
Engineering noncovalent π-stacked organic framework for intrinsic near-infrared photoactivated drug delivery 0.72
Id1 promotes clonal hematopoiesis in mice with Tet2 loss of function 1.00
DKC1-mediated pseudouridylation of rRNA targets hnRNP A1 to sustain IRES-dependent translation and ATF4-driven metabolic adaptation 1.00
Distinctive molecular features of radiation-induced thyroid cancers 0.68
Diverse oncogenes use common mechanisms to drive growth of major forms of human cancer 0.03
HMGB1 deforms nucleosomal DNA to generate a dynamic chromatin environment counteracting the effects of linker histone 1.00
Advancing precision photothermal therapy by integrating armored gold nanostars with real-time photoacoustic thermometry and imaging 1.00
Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTs 0.94
YAP regulates transcriptional programs for layer-specific periosteal expansion during fracture repair 1.00
DNA damage response pathway regulates Nrf2 in response to oxidative stress 0.05
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation 0.03
Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors 1.00
Src/FN1 pathway activation drives tumor cell cluster formation and metastasis in lung cancer: A promising therapeutic target 0.15
Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML 1.00
Cypin regulates K63-linked polyubiquitination to shape synaptic content 1.00
Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors 0.17
Discovery of an autoinhibited conformation in mesotrypsin reveals a strategy for selective serine protease inhibition 0.94
A universal chimeric antigen receptor (CAR)–fragment antibody binder (FAB) split system for cancer immunotherapy 0.82
IL-17 links the tumor suppressor LKB1 to gastrointestinal inflammation and polyposis 1.00
TGFβ-dependent signaling drives tumor growth and aberrant extracellular matrix dynamics in NF1-associated plexiform neurofibroma 0.98
Caspase-1–dependent pyroptosis converts αSMA+ CAFs into collagen-IIIhigh iCAFs to fuel chemoresistant cancer stem cells 0.94
Interaction between NF-κB and PLAC8 impairs autophagy providing a survival advantage to prostate cells transformed by cadmium 1.00
Leveraging dysregulated tumor metabolism for targeting anticancer bacteria 1.00
Chemokines kill bacteria without triggering antimicrobial resistance by binding anionic phospholipids 1.00
HDAC7 promotes renal cancer progression by reprogramming branched-chain amino acid metabolism 1.00
Low-dose radiation by radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in localized neuroblastoma 1.00
34 22.70
Genomic instability drives POSTN+ myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer 0.02
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma 0.95
A long-term image-derived AI-based risk model for primary prevention of breast cancer in individuals at high risk 0.57
Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder 1.00
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer 1.00
Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers 0.07
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome 0.03
LSD1 inhibition ameliorates congenital dyserythropoietic anemia type II 1.00
Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value 0.59
Cell-free DNA fragmentomes for noninvasive detection of liver cirrhosis and other diseases 0.78
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors 0.88
Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia 1.00
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells 0.84
Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models 1.00
A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma 1.00
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer 1.00
Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts 0.94
ZAP327 signaling domain–driven chimeric antigen receptor generates robust and long-term antitumor immunity in mouse models 1.00
An early clinical trial of 5-ALA sonodynamic therapy in recurrent high-grade glioma 1.00
Target antigen–displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma 1.00
Cationic nanogel–based nasal therapeutic HPV vaccine prevents the development of cervical cancer 0.02
DLL1-responsive PD-L1+ tumor-associated macrophages promote endocrine resistance in breast cancer 0.90
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses 0.99
Spatial profiling of human pancreatic ductal adenocarcinoma reveals molecular alterations associated with venous invasion 1.00
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer 0.73
The landscape of microbial associations in human cancer 0.05
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors 1.00
CAR Treg cells mediate linked suppression and infectious tolerance in islet transplantation in mice 0.18
Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer 0.10
Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models 0.50
Myeloma interaction with bone marrow stromal cells suppresses ciliogenesis and osteogenic potential in myeloma bone disease 0.04
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis 0.16
Podocyte YAP and TAZ hyperactivation drives glomerular epithelial proliferative diseases in mice and humans 0.50
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers 0.85
1 0.92
Cancer outcomes in women without upfront surgery for ductal carcinoma in situ: observational cohort study 0.92
16 8.30
Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism 1.00
Functional rescue of a disease-linked ERAD pathway mutation via alternative splicing 1.00
Protease-mediated PRC1 dissociation promotes H2AK119ub remodeling during stress responses 0.03
The transaminase-ω-amidase pathway senses oxidative stress to control glutamine metabolism and α-ketoglutarate levels in endothelial cells 0.05
TDP-43 directly inhibits mRNA accumulation in neurites through modulation of mRNA stability 1.00
Widespread mono- and oligoadenylation direct small noncoding RNA maturation versus degradation fates 1.00
Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. 0.03
RNF114 and RNF166 exemplify reader-writer E3 ligases that extend K11 polyubiquitin onto sites of MARUbylation. 1.00
Eliminating separase inhibition reveals absence of robust cohesin protection in oocyte metaphase II 0.25
Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis. 0.92
Parp7 generates an ADP-ribosyl degron that controls negative feedback of androgen signaling. 0.62
TERRA R-loops trigger a switch in telomere maintenance towards break-induced replication and PRIMPOL-dependent repair. 0.13
Mechanistic insight into anaphase bridge signaling to the abscission checkpoint 0.14
Autophagosomes anchor an AKAP11-dependent regulatory checkpoint that shapes neuronal PKA signaling 1.00
Annexin A5 controls VDAC1-dependent mitochondrial Ca2+ homeostasis and determines cellular susceptibility to apoptosis 0.05
CHD8 interacts with BCL11A to induce oncogenic transcription in triple negative breast cancer 0.08
1 1.00
Well-differentiated systemic mastocytosis: genetics, mast cell immunophenotypes, and KIT autophosphorylation 1.00
16 5.94
Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial 0.14
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial 0.13
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis 0.80
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.47
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial 1.00
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials 0.81
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.05
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial 0.36
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China 0.03
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.08
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.23
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.35
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.33
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial 0.23
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.55
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial 0.37
2 0.46
Breast cancer overall survival, annual risks of death, and survival gap apportionment in sub-Saharan Africa (ABC-DO): 7-year follow-up of a prospective cohort study 0.03
Substandard anticancer medications in clinical care settings and private pharmacies in sub-Saharan Africa: a systematic pharmaceutical investigation 0.43
43 18.20
Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study 0.17
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials 0.21
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial 0.33
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial 0.50
Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study 0.31
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study 0.19
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study 0.20
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study 0.94
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration 0.46
Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study 0.91
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial 1.00
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.39
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial 0.14
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial 0.28
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.10
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.29
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.26
Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial 1.00
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group 0.32
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.03
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials 0.03
Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study 0.18
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.58
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial 0.13
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.41
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study 0.15
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 0.34
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 0.64
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study 0.55
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial 1.00
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis 0.75
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial 1.00
Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study 0.31
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.47
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.21
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis 0.31
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.27
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis 0.30
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis 0.73
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study 0.21
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group 0.69
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 0.32
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study 0.59
35 16.17
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer 0.32
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations 0.17
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.28
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.21
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer 1.00
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.21
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease 1.00
A Phase 3 Trial of Brepocitinib in Dermatomyositis 0.83
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 0.58
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer 0.91
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors 1.00
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.38
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer 0.59
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.40
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.17
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.30
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.54
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.30
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.18
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 0.45
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.40
Nivolumab for Resected Stage III or IV Melanoma at 9 Years 0.31
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.05
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.14
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.32
Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling 1.00
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 0.36
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer 0.94
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 0.93
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.44
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.27
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.22
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.32
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 0.47
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.20
2 0.33
The conserved spliceosomal protein AtSF3B2 controls the floral transition by regulating transcription and splicing in Arabidopsis 0.11
ANAPHASE-PROMOTING COMPLEX/ANAPHASE-PROMOTING COMPLEX/CYCLOSOME coactivators maintain AURORA 1 kinase homeostasis during meiotic chromosome segregationcoactivators maintain AURORA 1 kinase homeostasis during meiotic chromosome segregation 0.22
1 0.10
Increase in second primary lung cancers in a nation-wide cohort study from Sweden 0.10

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.